<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0311211255
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2016
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        CoDICERAN 16/12.5 film-coated tablet
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CANDESARTAN CILEXETIL,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        16,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        41.35
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="LEK PHARMACEUTICALS D.D." />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            LEK PHARMACEUTICALS D.D.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 360]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Farouk, Maamoun Tamer & CO
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            SANDOZ
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA06
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The name of your medication is Codiceran Sandoz. It is used to treat high blood pressure (hypertension) in adult patients. It contains two active substances: Candesartan cilexetil and hydrochlorothiazide. They work together to lower your blood pressure.</p><p>&nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Candesartan cilexetil belongs to a group of drugs known as angiotensin II receptor antagonists. It works by relaxing and expanding your blood vessels. This helps to lower your blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrochlorothiazide belongs to a group of medicines known as diuretics (water tablets). It helps your body eliminate water and salts such as sodium in the urine. This helps to lower your blood pressure.</p><p>&nbsp;</p><p>Your doctor will prescribe Codiceran if your blood pressure could not be properly controlled by candesartan cilexetil or hydrochlorothiazide alone.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Codiceran Sandoz</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to candesartan cilexetil or hydrochlorothiazide or any of the other ingredients of this medicine listed in Section 6.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you are allergic to sulfonamide medicines. If you are not sure whether this applies to you, please ask your doctor.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; during the last 6&nbsp;months of pregnancy (it is advisable to also avoid Codiceran in the early phase of pregnancy, see Section &ldquo;Pregnancy and lactation&rdquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have serious liver or kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have a serious liver disorder or biliary stasis (a problem with the bile flow from the gallbladder).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have persistently low potassium levels in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have persistently high calcium levels in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have ever had gout.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; if you have diabetes mellitus or impaired kidney function and are being treated with a blood pressure lowering drug which contains aliskiren.</p><p>&nbsp;</p><p>If you are not sure whether one of the above applies to you, speak to your doctor or pharmacist before taking Codiceran Sandoz.</p><p>&nbsp;</p><p>Warnings and precautions</p><p>Please talk to your doctor or pharmacist before taking Codiceran if:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have <strong>heart, liver or kidney </strong>problems.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have recently had a <strong>kidney transplant</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have<strong> </strong>to<strong> vomit</strong>, have recently seriously vomited or have <strong>diarrhoea</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have an <strong>adrenal disorder </strong>known as Conn Syndrome (also called primary hyperaldosteronism).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have <strong>diabetes</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had a disease called <strong>systemic lupus erythematosus</strong> (SLE).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have <strong>low blood pressure</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have previously suffered a <strong>stroke</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have ever had <strong>allergies</strong> or <strong>asthma</strong>.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have experienced any <strong>breathing or lung problems</strong> (including inflammation or fluid accumulation in the lungs) in the past after taking hydrochlorothiazide. If you develop severe shortness of breath or difficulty breathing after taking Codiceran Sandoz, see a doctor immediately.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you are taking any of the following medicines for the treatment of <strong>high blood pressure</strong>:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an <strong>ACE inhibitor </strong>(e.g., enalapril, lisinopril, ramipril), especially if you have kidney problems due to diabetes mellitus</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>aliskiren</strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you have or have had <strong>skin cancer</strong>. Check your skin regularly for new <strong>lesions</strong> and report immediately to your doctor if you develop an unexpected skin lesion during treatment.</p><p>Treatment with hydrochlorothiazide, especially high-dose long-term use, may increase the risk of some types of skin and lip cancer (white skin cancer). Avoid exposure to sunlight and UV rays or use appropriate sun protection while taking Codiceran Sandoz.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; you notice your <strong>vision getting worse</strong> or have <strong>eye pain</strong>. These may be symptoms of fluid accumulation in the vascular layer of the eye (choroidal effusion) or an increase in pressure in your eye and occur within hours to weeks after taking Codiceran Sandoz. If these conditions are not treated, permanent vision loss may occur. If you have had an allergy to penicillin or sulfonamides before, you are more likely to suffer from these conditions.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; tell your doctor if you believe that you may be pregnant (<u>or could become pregnant</u>). Taking Codiceran in the early stage of <strong>pregnancy</strong> is not recommended and Codiceran must not be taken if you are more than 3 months pregnant, as taking Codiceran at this stage may cause serious harm to your unborn child (see section &ldquo;Pregnancy&rdquo;).</p><p>&nbsp;</p><p>Your doctor may check your kidney function, blood pressure, and blood electrolyte values (e.g., potassium) at regular intervals.</p><p>See also the section &ldquo;Do not take Codiceran Sandoz&rdquo;.</p><p>&nbsp;</p><p>If one of the above circumstances applies to you, your doctor may want to see you more frequently and conduct some examinations.</p><p>&nbsp;</p><p>If you are planning to have an operation, please inform your doctor or dentist that you are taking Codiceran Sandoz. The reason for this is that, in combination with some anaesthetics, Codiceran can result in a severe drop in blood pressure.</p><p>&nbsp;</p><p>Codiceran could cause increased sensitivity of the skin to the sun.</p><p>&nbsp;</p><p><strong>Children and adolescents</strong></p><p>There is no experience in the use of Codiceran in children and adolescents (under the age of 18&nbsp;years). Thus, Codiceran should not be given to children and adolescents.</p><p>&nbsp;</p><p>Talk to your doctor if you are an <strong>athlete and are participating in a doping check</strong>, as Codiceran contains an active substance that can lead to positive results during doping checks.</p><p>&nbsp;</p><p>Taking Codiceran with other medicines</p><p>Tell your doctor or pharmacist if you are taking/using, have recently taken/used or might take/use any other medicines.</p><p>&nbsp;</p><p>Codiceran can affect the efficacy of some other drugs and some drugs may have an effect on Codiceran Sandoz. If you are taking certain other medications, your doctor may have to carry out blood tests from time to time.</p><p>&nbsp;</p><p>In particular, tell your doctor if you are taking any of the following medicines as your doctor may need to adjust your dosage and/or take other precautions:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; an ACE inhibitor or aliskiren (see also the section &ldquo;Do not take Codiceran Sandoz&rdquo; and &ldquo;Warnings and precautions&rdquo;)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other medicines that help lower your blood pressure, medicines containing aliskiren, diazoxide and ACE inhibitors such as enalapril, captopril, lisinopril or ramipril</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drugs to control your heart rhythm (antiarrhythmic drugs), such as digoxin and beta-blockers</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; non-steroidal anti-inflammatories (NSAIDs) such as ibuprofen, naproxen, diclofenac, celecoxib or etoricoxib (medication to reduce pain and inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; acetylsalicylic acid, if you are taking more than 3&nbsp;g per day (medication to reduce pain and inflammation)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; potassium preparations or salt replacements containing potassium (medication to increase the amount of potassium in your blood)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; heparin (blood-thinning medicine)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; diuretic medication</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; lithium (a drug for mental disorders)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; drugs that may be affected by potassium blood levels, such as some antipsychotic drugs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines to lower your cholesterol such as colestipol or cholestyramine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; calcium or vitamin D supplements</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; anticholinergics, such as atropine and biperiden</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amantadine (for the treatment of Parkinson&rsquo;s disease or for serious infections caused by viruses)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; barbiturates (a type of sedative also used to treat epilepsy)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for treating cancer</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; steroids such as prednisolone</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; pituitary hormones (ACTH)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; medicines for diabetes (tablets or insulin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; laxatives</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; amphotericin (for the treatment of fungal infections)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; carbenoxolone (for the treatment of oesophageal disorders or mouth ulcers)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; penicillin or co-trimoxazole, also known as trimethoprim and sulfamethoxazole (an antibiotic)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; cyclosporine, a drug used in organ transplantation to prevent organ rejection</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; other drugs that increase the blood pressure-lowering effect, such as baclofen (a drug used to relieve spasticity), amifostine (used in cancer treatment), and some antipsychotic drugs</p><p>&nbsp;</p><p>Taking Codiceran with food, drink and alcohol</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; You can take Codiceran either with or without food.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have been prescribed Codiceran Sandoz, speak to your doctor before you drink any alcohol. Alcohol may cause you to feel faint or dizzy.</p><p>&nbsp;</p><p>Pregnancy and breastfeeding</p><p><u>Pregnancy</u></p><p>Tell your doctor if you believe that you may be pregnant (or could become pregnant). Your doctor will generally advise you to stop taking Codiceran before you become pregnant, or as soon as you know you are pregnant, and will recommend a different medicine. Taking Codiceran in the early stage of pregnancy is not recommended and Codiceran must not be taken if you are more than 3&nbsp;months pregnant, as taking Codiceran at this stage may cause serious harm to your unborn child.</p><p><em>&nbsp;</em></p><p><u>Breastfeeding</u></p><p>Tell your doctor if you are breastfeeding or would like to start breastfeeding. Codiceran is not recommended for mothers who are breastfeeding, and your doctor may choose another treatment for you if you wish to breastfeed, especially if your baby is newborn or was born prematurely.</p><p>&nbsp;</p><p>Driving and using machines</p><p><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Title: Warndreick - Description: Symbol: Achtung" style='width:30.75pt;
 height:27pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF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">
 <v:imagedata src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title="" cropright="-320f"/>
</v:shape><![endif]--><img width="41" height="36" alt="Title: Warndreick - Description: Symbol: Achtung" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" />&nbsp;Caution: This medicine may impair the ability to react and the ability to drive.</p><p>&nbsp;</p><p>Some people may feel tired or dizzy when taking Codiceran Sandoz. If this is the case with you, do not drive a vehicle and do not operate any tools or machinery.</p><p>&nbsp;</p><p>Codiceran contains lactose</p><p>Please only take Codiceran after consulting your doctor if you know that you suffer from an intolerance to certain sugars.</p><p>&nbsp;</p><p>Codiceran contains sodium.</p><p>This medicine contains less than 1&nbsp;mmol of sodium (23&nbsp;mg) per tablet, i.e., it is virtually &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. It is important to take Candesartan/HTC Sandoz every day.</p><p>&nbsp;</p><p>The usual dose of Codiceran is one tablet once a day.</p><p>&nbsp;</p><p>Swallow the tablet with water.</p><p>Try to take the tablet at the same time every day. This will help you remember to take it.</p><p>&nbsp;</p><p>If you have taken more Codiceran than you should have</p><p>If you have taken a larger amount of Codiceran than prescribed by your doctor, please consult your doctor or pharmacist immediately to obtain advice.</p><p>&nbsp;</p><p>If you have forgotten to take Codiceran Sandoz</p><p>Do not take a double dose to make up for the forgotten dose. Just take the next dose as usual.</p><p>&nbsp;</p><p>If you stop taking Codiceran Sandoz</p><p>If you discontinue the use of Codiceran Sandoz, your blood pressure may increase again. Therefore, do not stop taking Codiceran without first speaking to your doctor.</p><p>&nbsp;</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them. It is important that you should be aware of these possible side effects. Some of the side effects of Codiceran are caused by candesartan cilexetil and some by hydrochlorothiazide.</p><p>&nbsp;</p><p><strong>Do not continue to take Codiceran and consult a doctor immediately if you suffer one of the following allergic reactions:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty in breathing with or without swelling of the face, lips, tongue and/or throat.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat that may cause difficulty swallowing.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Serious itching of the skin (with pustule-like swellings).</p><p>&nbsp;</p><p><strong>Also stop taking Codiceran and see a doctor immediately if you</strong> develop acute shortness of breath (signs are severe shortness of breath, fever, weakness and confusion). This is a very rare side effect (may affect up to 1 in 10,000 persons treated).</p><p>&nbsp;</p><p>Codiceran can lead to a reduction in the number of white blood cells. Your resistance to infections may be reduced and you may feel tired or develop an infection or fever. If this happens, consult your doctor. Your doctor may carry out occasional blood tests to check whether Codiceran has previously had an effect on your blood (agranulocytosis).</p><p><strong>&nbsp;</strong></p><p><strong>Other possible side effects include:</strong></p><p><strong>&nbsp;</strong></p><p><strong>Common</strong> (may affect up to 1 in 10 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Change in blood test results:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduced amount of sodium in your blood. In serious cases, you may feel weakness, a lack of energy or muscle cramps.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased or decreased amount of potassium in your blood, especially when you have previously had kidney problems or cardiac insufficiency. In serious cases you may experience tiredness, weakness, irregular heartbeat or a tingling sensation (&ldquo;formication&rdquo;).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An increased amount of cholesterol, sugar or uric acid in your blood.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sugar in your urine</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness/feeling of spinning or weakness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Headache</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Infection of the respiratory tract</p><p>&nbsp;</p><p><strong>Uncommon</strong> (may affect up to 1 in 100 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Low blood pressure. This may cause you to feel faint or dizzy</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Loss of appetite, diarrhoea, constipation, stomach irritation</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Rash, hives, rash caused by sensitivity to sunlight</p><p>&nbsp;</p><p><strong>Rare</strong> (may affect up to 1 in 1,000 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Yellowing of the skin or of the whites of the eyes (jaundice). If this applies to you, inform your doctor immediately</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your kidney function may be affected, especially if you have kidney problems or cardiac insufficiency</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty sleeping, depression, restlessness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Tingling or itching in your arms or legs</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blurred vision over a short period of time</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Abnormal heartbeat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Difficulty breathing (including pneumonia and fluid in the lungs)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Elevated temperature (fever)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inflammation of the pancreas. This causes moderate to severe stomach pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle cramps</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Damage to blood vessels causing red or purple spots in the skin</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A reduction in the number of your red or white blood cells or platelets. You may feel tired or develop an infection, fever or mild bruising</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A significant, rapidly developing rash, with blistering or peeling of the skin and possibly blistering in the mouth</p><p>&nbsp;</p><p><strong>Very rare</strong> (may affect up to 1 in 10,000 persons treated)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Swelling of the face, lips, tongue and/or throat</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Itching</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Backache, pain in the joints and muscles</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Changes in liver function, including inflammation of the liver (hepatitis). You may notice tiredness, your skin and the whites of your eyes may develop a yellow tinge or you may develop flu-like symptoms</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cough</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Nausea</p><p>&nbsp;</p><p><strong>Not known</strong> (frequency cannot be estimated from the available data)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sudden near-sightedness</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Impaired vision or pain in your eyes due to high pressure (possible signs of fluid accumulation in the vascular layer of the eye (choroidal effusion) or acute angle closure glaucoma)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Systemic and cutaneous lupus erythematosus (allergic condition with fever, joint pain and rash, which may also be accompanied by redness, blistering, peeling and knot formation in the skin)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhoea</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Skin and lip cancer (non-melanoma skin cancer)</p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>To report any side effect(s)</strong></p><p>&middot;&nbsp;&nbsp;&nbsp; Saudi Arabia</p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_16" o:spid="_x0000_s1028"
 type="#_x0000_t202" style='position:absolute;margin-left:0;margin-top:11.3pt;
 width:429pt;height:104.9pt;z-index:251659264;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:left;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF
dyTewfKKEqcMCKEmHfgZgaE8wMW+SSwc27JvS/v23KTJgkoXFsu+P+c7Ol5vDoMTe0zZBl/LVVlJ
gV4HY31Xy4/tS3EvRSbwBlzwWMsjZrlprq/W22PELHjb51r2RPFBqax7HCCXIaLnThvSAMTP1KkI
+gs6VLdVdad08ISeCho1ZLN+whZ2jsTzgcsnJwldluLxNDiyagkxOquB2Knae/OLUsyEkjenmdzb
mG/YhlRnCWPnb8C898bRJGtQvEOiVxjYhtLOxs8AySiT4JuDystlVV4WPeM6tK3VaILeDZxIOSsu
ti/jidNGNZ3/J08yC1dNv9v8AAAA//8DAFBLAwQUAAYACAAAACEArTA/8cEAAAAyAQAACwAAAF9y
ZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj39ubi6AgeJtl2G9m6vYx
jeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLBBhaZ4ljBkFLYSMl6oAm5
8IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZTVuvrxO59CNCmoj3vCwj
MfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAAACEAHGFcgNEEAAD+HwAA
HwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWzsWd1OIzcUvq/Ud7B81V6Qf9gl2mEb
wma1EmIjwoprx+NJLDz21HZCsk/TZ+mT9bNnAuGnu7QbUIsmCDj2OTlzfP7n+N37Va7IUlgnjU5o
u9GiRGhuUqlnCf1yMdp7S4nzTKdMGS0SuhaOvj/6+ad3rD+zrJhLTsBBuz5L6Nz7ot9sOj4XOXMN
UwgNXGZszjyWdtZMLbsG51w1O63WQTNnUtOjW1YnzDOysPJfsFKGX4l0yPSSObBUvL+9U8mo+I9z
Zn29/GiLSTG2QXJ+thxbItOEQnOa5VARbVaIigzL5r1vzW4ZrDKbB3qTZWSV0MNWq9cFq3VCu512
+y3gyE6sPOHA7/d62AMBB0W72+10NhR8/vnbLPj8w3eYQMxSHABbIroiCKiXD8/cPtgc+iIIeGxW
BFub8wd64lfYhajRzq44hZ1cqRGoruQYtbNh7irF7kgvN0di/cI6/1GYnAQgoVZwH4Viy1PnS5E2
JOG8ziiZjqRScbF2Q2XJkqmEwoNTc02JYs5jM6Gj+AnHxtPufE1pcp3Qg+5+qzz+NsvwrBueU8X4
1UMO4Kd0ybZSi19NojWCWtN1EG2K/9CzNTgT/MIVfCTB+hTSjZlFWGITAe4/40+mDOThShaUzI39
en8v0CFEgKHkGuGdUPf7glmBw37SDt7Z7vXAzsdFb/9NBwu7jZluY/QiHxoorB2limCg92oDZtbk
l8amg/BUoJjmeHZC/QYceqyAQA7hYjCIMDd5wfypnhSI5tKtgiovVpfMFpVtPbzxzEzmrBCPmbik
jU5tBgtvMlnZv9RlQCjnJ36tRPTlqPHgzDmzp1EIAOcBiL5R8GORVdDYu9JLYtwGf9jGDjL/DbqI
xVcqU9tAavFUxUIyFnrvywSa/IpTt5EBAlZkGby4dF/IzLzUxK8LkTGORHQhc+HImbgm5yZnmpKC
aeOAaHXwc9DqtvZbPfx2APWAlZ7PRyyXKqQW5H0+Z9aJaJqoBsGekTl3z8YcKoUag778ETkbDwk3
2jPuidRlcULtIxO2SCUZWDaVrB8CGZYKX4xq1mkIpfNHbQEFPsEWQ6ORGVCbto1wDCMcRmP0YILO
AyP0Dl+VEcSNGqNqy6gK+q1D6zWE1p9/1GGz86yLFPSEsOn2OmgcaahPsSwRtUTdxQZaFaGRwfcq
ihBtdyrSD9crNCCLEfLpVvYeGvTwwobKcyfdvUGSK9NdqDm9J6W76WKIKhRLUUJN1SHVBXK3pX27
QF7MBTlDI2E0U2QM3eeMm6WcSXQhXJAh3MkK8gvK6K91mdx9l1XHex3v1Qv0yzTEk9HJgAyZUjG0
he2T9iE+dSmvSzk0UJfy3ad4DA1fJrQ/7GHAqvrkXizHV9q/nyuQRUI1Zr1h7mvlFZxAm0mEnvCa
u9u+BL3v/3TkwPpzJfXVUEl+VQ2fMcn6/oAcU2DJxYnhixyNVjkltyIMdjA/mMsC8wPbD9Nm+ylt
V93wzWxDF7yR2sXsN5elrDEzy4Zj92x/+y7xyFSpnmQ8aRBWt2h1i/aiLdqlmDrpBWGpaNSh/czV
8zZD/seGlKnYO/nwWuf/2xOIfzZHfHVXIY+WF2ze3vgtnJgU57j4KW8cyytBUIR72ua9m+/oxNVN
fbhe314f/QUAAP//AwBQSwMEFAAGAAgAAAAhAJxOXiHiBgAAOhwAABoAAABjbGlwYm9hcmQvdGhl
bWUvdGhlbWUxLnhtbOxZT28bRRS/I/EdRntv4/+NozpV7NgNtGmj2C3qcbwe704zu7OaGSf1DbVH
JCREQRyoxI0DAiq1EpfyaQJFUKR+Bd7M7K534jVJ2wgqaA7x7tvfvP/vzZvdy1fuRQwdEiEpjzte
9WLFQyT2+YTGQce7NRpcWPeQVDieYMZj0vHmRHpXNt9/7zLe8BlNxhyLySgkEUHAKJYbuOOFSiUb
a2vSBzKWF3lCYng25SLCCm5FsDYR+AgERGytVqm01iJMY28TOCrNqM/gX6ykJvhMDDUbgmIcgfSb
0yn1icFODqoaIeeyxwQ6xKzjAc8JPxqRe8pDDEsFDzpexfx5a5uX1/BGuoipFWsL6wbmL12XLpgc
1IxMEYxzodVBo31pO+dvAEwt4/r9fq9fzfkZAPZ9sNTqUuTZGKxXuxnPAsheLvPuVZqVhosv8K8v
6dzudrvNdqqLZWpA9rKxhF+vtBpbNQdvQBbfXMI3ulu9XsvBG5DFt5bwg0vtVsPFG1DIaHywhNYB
HQxS7jlkytlOKXwd4OuVFL5AQTbk2aVFTHmsVuVahO9yMQCABjKsaIzUPCFT7ENO9nA0FhRrAXiD
4MITS/LlEknLQtIXNFEd78MEx14B8vLZ9y+fPUHH958e3//p+MGD4/s/WkbOqh0cB8VVL7797M9H
H6M/nnzz4uEX5XhZxP/6wye//Px5ORDKZ2He8y8f//b08fOvPv39u4cl8C2Bx0X4iEZEohvkCO3z
CAwzXnE1J2PxaitGIabFFVtxIHGMtZQS/n0VOugbc8zS6Dh6dInrwdsC2kcZ8OrsrqPwMBQzRUsk
XwsjB7jLOetyUeqFa1pWwc2jWRyUCxezIm4f48My2T0cO/HtzxLom1laOob3QuKoucdwrHBAYqKQ
fsYPCCmx7g6ljl93qS+45FOF7lDUxbTUJSM6drJpsWiHRhCXeZnNEG/HN7u3UZezMqu3yaGLhKrA
rET5EWGOG6/imcJRGcsRjljR4dexCsuUHM6FX8T1pYJIB4Rx1J8QKcvW3BRgbyHo1zB0rNKw77J5
5CKFogdlPK9jzovIbX7QC3GUlGGHNA6L2A/kAaQoRntclcF3uVsh+h7igOOV4b5NiRPu07vBLRo4
Ki0SRD+ZiZJYXiXcyd/hnE0xMa0GmrrTqyMa/13jZhQ6t5Vwfo0bWuXzrx+V6P22tuwt2L3Kambn
RKNehTvZnntcTOjb35238SzeI1AQy1vUu+b8rjl7//nmvKqez78lL7owNGg9i9hB24zd0cqpe0oZ
G6o5I9elGbwl7D2TARD1OnO6JPkpLAnhUlcyCHBwgcBmDRJcfURVOAxxAkN71dNMApmyDiRKuITD
oiGX8tZ4GPyVPWo29SHEdg6J1S6fWHJdk7OzRs7GaBWYA20mqK4ZnFVY/VLKFGx7HWFVrdSZpVWN
aqYpOtJyk7WLzaEcXJ6bBsTcmzDUIBiFwMstON9r0XDYwYxMtN9tjLKwmCicZ4hkiCckjZG2ezlG
VROkLFeWDNF22GTQB8dTvFaQ1tZs30DaWYJUFNdYIS6L3ptEKcvgRZSA28lyZHGxOFmMjjpeu1lr
esjHScebwjkZLqMEoi71HIlZAG+YfCVs2p9azKbKF9FsZ4a5RVCFVx/W70sGO30gEVJtYxna1DCP
0hRgsZZk9a81wa3nZUBJNzqbFvV1SIZ/TQvwoxtaMp0SXxWDXaBo39nbtJXymSJiGE6O0JjNxD6G
8OtUBXsmVMLrDtMR9A28m9PeNo/c5pwWXfGNmMFZOmZJiNN2q0s0q2QLNw0p18HcFdQD20p1N8a9
uimm5M/JlGIa/89M0fsJvH2oT3QEfHjRKzDSldLxuFAhhy6UhNQfCBgcTO+AbIH3u/AYkgreSptf
QQ71r605y8OUNRwi1T4NkKCwH6lQELIHbclk3ynMquneZVmylJHJqIK6MrFqj8khYSPdA1t6b/dQ
CKluuknaBgzuZP6592kFjQM95BTrzelk+d5ra+CfnnxsMYNRbh82A03m/1zFfDxY7Kp2vVme7b1F
Q/SDxZjVyKoChBW2gnZa9q+pwitutbZjLVlca2bKQRSXLQZiPhAl8A4J6X+w/1HhM/sFQ2+oI74P
vRXBxwvNDNIGsvqCHTyQbpCWOIbByRJtMmlW1rXp6KS9lm3W5zzp5nJPOFtrdpZ4v6Kz8+HMFefU
4nk6O/Ww42tLW+lqiOzJEgXSNDvImMCUfcnaxQkaB9WOB1+TIND34Aq+R3lAq2laTdPgCj4ywbBk
vwx1vPQio8BzS8kx9YxSzzCNjNLIKM2MAsNZ+g0mo7SgU+nPJvDZTv94KPtCAhNc+kUla6rO577N
vwAAAP//AwBQSwMEFAAGAAgAAAAhAFOr2/ztAAAAzQEAACoAAABjbGlwYm9hcmQvZHJhd2luZ3Mv
X3JlbHMvZHJhd2luZzEueG1sLnJlbHOskcFqAyEQQO+F/oPMvbqbQykhbnJoCzn0UtIPGHTWlayj
qAnJ31caShsI9NLLgDP65jmzWp/CLI6Ui4+soZcdCGITrWen4WP3+vAEolRki3Nk0nCmAuvh/m71
TjPW9qhMPhXRKFw0TLWmpVLFTBSwyJiIW2WMOWBtx+xUQrNHR2rRdY8q/2bAcMUUW6shb+0CxO6c
Wue/2XEcvaHnaA6BuN5ooWrzogbE7KhqkPKSucReNldQtzX6/9SY2ofy7Hn/oxLQzzUuORlp88Ft
ymhRuniUBb8vvUXbxvByqpQZv0TV1RKGTwAAAP//AwBQSwECLQAUAAYACAAAACEAu+VIlAUBAAAe
AgAAEwAAAAAAAAAAAAAAAAAAAAAAW0NvbnRlbnRfVHlwZXNdLnhtbFBLAQItABQABgAIAAAAIQCt
MD/xwQAAADIBAAALAAAAAAAAAAAAAAAAADYBAABfcmVscy8ucmVsc1BLAQItABQABgAIAAAAIQAc
YVyA0QQAAP4fAAAfAAAAAAAAAAAAAAAAACACAABjbGlwYm9hcmQvZHJhd2luZ3MvZHJhd2luZzEu
eG1sUEsBAi0AFAAGAAgAAAAhAJxOXiHiBgAAOhwAABoAAAAAAAAAAAAAAAAALgcAAGNsaXBib2Fy
ZC90aGVtZS90aGVtZTEueG1sUEsBAi0AFAAGAAgAAAAhAFOr2/ztAAAAzQEAACoAAAAAAAAAAAAA
AAAASA4AAGNsaXBib2FyZC9kcmF3aW5ncy9fcmVscy9kcmF3aW5nMS54bWwucmVsc1BLBQYAAAAA
BQAFAGcBAAB9DwAAAAA=
" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoPlainText><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
    layout-grid-mode:line'><span style='mso-spacerun:yes'> </span>NPC contact
    information Saudi Arabia:<o:p></o:p></span></p>
    <p class=MsoPlainText><span style='font-size:11.0pt;font-family:"Times New Roman",serif;
    layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo9'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New";layout-grid-mode:
    line'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>The
    National Pharmacovigilance Centre (NPC):<o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo9'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New";layout-grid-mode:
    line'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>SFDA Call
    Center: 19999<o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo9'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New";layout-grid-mode:
    line'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>E-mail: </span><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-size:11.0pt;
    font-family:"Times New Roman",serif;color:windowtext;layout-grid-mode:line;
    text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
    style='font-size:11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:
    line'><o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo9'><![if !supportLists]><span style='font-size:11.0pt;
    font-family:"Courier New";mso-fareast-font-family:"Courier New";layout-grid-mode:
    line'><span style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span style='font-size:
    11.0pt;font-family:"Times New Roman",serif;layout-grid-mode:line'>Website
    ade.sfda.gov.sa<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=DE style='mso-bidi-font-size:11.0pt;
    layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;margin-left:.3pt;margin-top:126.6pt;width:429pt;
 height:89.25pt;z-index:251661312;visibility:visible;mso-wrap-style:square;
 mso-width-percent:0;mso-height-percent:0;mso-wrap-distance-left:9pt;
 mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal style='margin-top:2.0pt;margin-right:0in;margin-bottom:
    2.0pt;margin-left:0in;mso-add-space:auto;line-height:12.6pt;text-autospace:
    none'><span lang=DE style='mso-bidi-font-size:11.0pt;layout-grid-mode:line'>Patient
    Safety Department Novartis Consulting AG - Saudi Arabia:<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst style='margin-top:2.0pt;margin-right:
    0in;margin-bottom:2.0pt;margin-left:.25in;mso-add-space:auto;text-indent:
    -.25in;line-height:12.6pt;mso-list:l4 level1 lfo8;text-autospace:none'><![if !supportLists]><span
    lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
    mso-fareast-font-family:"Courier New";layout-grid-mode:line'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=DE
    style='mso-bidi-font-size:11.0pt;layout-grid-mode:line'>Toll Free Number: 8001240078<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-top:2.0pt;margin-right:
    0in;margin-bottom:2.0pt;margin-left:.25in;mso-add-space:auto;text-indent:
    -.25in;line-height:12.6pt;mso-list:l4 level1 lfo8;text-autospace:none'><![if !supportLists]><span
    lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
    mso-fareast-font-family:"Courier New";layout-grid-mode:line'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=DE
    style='mso-bidi-font-size:11.0pt;layout-grid-mode:line'>Phone:
    +966112658100<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle style='margin-top:2.0pt;margin-right:
    0in;margin-bottom:2.0pt;margin-left:.25in;mso-add-space:auto;text-indent:
    -.25in;line-height:12.6pt;mso-list:l4 level1 lfo8;text-autospace:none'><![if !supportLists]><span
    lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
    mso-fareast-font-family:"Courier New";layout-grid-mode:line'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=DE
    style='mso-bidi-font-size:11.0pt;layout-grid-mode:line'>Fax: +966112658107<o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast style='margin-left:.25in;mso-add-space:
    auto;text-indent:-.25in;mso-list:l4 level1 lfo8;text-autospace:none'><![if !supportLists]><span
    lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
    mso-fareast-font-family:"Courier New";layout-grid-mode:line'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=DE
    style='mso-bidi-font-size:11.0pt;layout-grid-mode:line'>Email:&nbsp;adverse.events@novartis.com<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=DE style='mso-bidi-font-size:11.0pt;
    layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="146" alt="Text Box:  NPC contact information Saudi Arabia:

o	The National Pharmacovigilance Centre (NPC):
o	SFDA Call Center: 19999
o	E-mail: npc.drug@sfda.gov.sa
o	Website ade.sfda.gov.sa

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="125" alt="Text Box: Patient Safety Department Novartis Consulting AG - Saudi Arabia:
o	Toll Free Number: 8001240078
o	Phone: +966112658100
o	Fax: +966112658107
o	Email: adverse.events@novartis.com

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><p>&nbsp;</p><ul><br /><li><strong>Other GCC states</strong></li><li><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_15"
      o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
      left:0;text-align:left;margin-left:0;margin-top:3.5pt;width:429pt;
      height:23.25pt;text-indent:0;z-index:251660288;visibility:visible;
      mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
      mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
      mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
      mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
      mso-position-vertical:absolute;mso-position-vertical-relative:text;
      mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
      mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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=
" fillcolor="window" strokeweight=".5pt">
      <v:path arrowok="t"/>
      <v:textbox>
       <![if !mso]>
       <table cellpadding=0 cellspacing=0 width="100%">
        <tr>
         <td><![endif]>
         <div>
         <p class=MsoListParagraph style='text-indent:-.25in;mso-list:l5 level1 lfo7;
         mso-layout-grid-align:none;text-autospace:none'><![if !supportLists]><span
         lang=DE style='font-size:12.0pt;mso-bidi-font-size:11.0pt;layout-grid-mode:
         line'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         </span></span></span><![endif]><span dir=LTR></span><span lang=DE
         style='mso-bidi-font-size:11.0pt;layout-grid-mode:line'>Please contact
         the relevant competent authority. <o:p></o:p></span></p>
         <p class=Default><span lang=DE-AT style='font-size:11.0pt;font-family:
         "Times New Roman",serif;color:windowtext;layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
         <p class=MsoNormal><span lang=DE style='mso-bidi-font-size:11.0pt;
         layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
         </div>
         <![if !mso]></td>
        </tr>
       </table>
       <![endif]></v:textbox>
      <w:wrap anchorx="margin"/>
     </v:shape><![endif]--><img width="578" height="37" alt="Text Box: -	Please contact the relevant competent authority. 


" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.gif" />&nbsp;</li></ul><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>&nbsp;</p><p>Do not use this medicine after the expiry date which is stated on the carton and on the bottle/blister after &ldquo;EXP&rdquo;. The expiry date refers to the last day of that month.</p><p>&nbsp;</p><p>Store below 30&deg;C. Store in the original package in order to protect from moisture.</p><p>&nbsp;</p><p>Shelf life 24 months</p><p>&nbsp;</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substances are candesartan cilexetil and hydrochlorothiazide.</p><p>.</p><p><strong><u>Codiceran 16&nbsp;mg/12.5&nbsp;mg:</u></strong></p><p>Each tablet contains 16&nbsp;mg candesartan cilexetil and 12.5&nbsp;mg hydrochlorothiazide.</p><p>&nbsp;</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are:</p><p>Lactose monohydrate (see end section 2), corn starch, povidone K-30, carrageenan, croscarmellose sodium, magnesium stearate; <u>additionally with Codiceran 16&nbsp;mg/12.5&nbsp;mg:</u> Iron oxide red (E&nbsp;172), iron oxide yellow (E&nbsp;172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Codiceran 16 mg/12.5 mg:
Apricot, marbled, oval, biconvex tablets, with a score line on both sides.

The score line is only to facilitate breaking the tablet for ease of swallowing and not to divide it into equal doses.

Pack Sizes:
Aluminum/aluminum blister with desiccant: 28 tablets

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Marketing Authorisation Holder :</strong></p><p>Sandoz GmbH</p><p>Biochemiestrasse 10, 6250</p><p>Kundl, Austria</p><p><strong>&nbsp;</strong></p><p><strong>Manufacturer:</strong></p><p>Lek Pharmaceuticals dd</p><p>Ljubljana, Slovenia</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                May 2022.
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">اسم دوائك هو كوديسيران ساندوز. ويُستخدم لعلاج ارتفاع ضغط الدم (فرط ضغط الدم) لدى المرضى البالغين. ويحتوي على مادتين فعالتين: سيليكسيتيل كانديسارتان وهيدروكلوروثيازيد. وتعملان معًا لخفض ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي سيليكسيتيل كانديسارتان إلى مجموعة من العقاقير تعرف باسم مضادات مستقبلات أنجيوتنسين 2. وهو يعمل عن طريق إرخاء الأوعية الدموية وتوسيعها. وبالتالي فهو يساعد على خفض ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ينتمي هيدروكلوروثيازيد إلى مجموعة من الأدوية تُعرف باسم مدرات البول (أقراص الماء). وهو يساعد جسمك على التخلص من الماء والأملاح مثل الصوديوم في البول. وبالتالي فهو يساعد على خفض ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">سيصف لك طبيبك كوديسيران إذا لم يكن من الممكن التحكم في ضغط الدم لديك على نحوٍ صحيح بواسطة سيليكسيتيل الكانديسارتان أو هيدروكلوروثيازيد وحده.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">لا تتناول كوديسيران ساندوز في الحالات التالية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت لديك حساسية تجاه سيليكسيتيل الكانديسارتان أو هيدروكلوروثيازيد أو أي من المكونات الأخرى لهذا الدواء المدرجة في القسم 6.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من حساسية تجاه أدوية سلفوناميد. إذا لم تكن متأكدًا مما إذا كان هذا ينطبق عليك، فيُرجى سؤال طبيبك.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خلال الأشهر الستة الأخيرة من الحمل (يُنصح أيضًا بتجنب كوديسيران في المرحلة المبكرة من الحمل، انظري قسم &quot;الحمل&nbsp;والرضاعة&quot;).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مشكلات خطيرة في الكبد أو الكلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطراب خطير في الكبد أو الركود الصفراوي (مشكلة في تدفق الصفراء من المرارة).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت مستويات البوتاسيوم في دمك منخفضة باستمرار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كانت مستويات الكالسيوم في دمك مرتفعة باستمرار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت قد أصبت بالنقرس من قبل.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من داء السكري أو قصور في وظائف الكلى وتتلقى علاجًا بعقار لخفض ضغط الدم يحتوي على أليسكيرين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا لم تكن متأكدًا مما إذا كان أي مما سبق ينطبق عليك أم لا، فتحدث إلى طبيبك أو الصيدلي قبل تناول كوديسيران ساندوز.</p><p dir="RTL">&nbsp;</p><p dir="RTL">التحذيرات والاحتياطات</p><p dir="RTL">يُرجى التحدث إلى طبيبك أو الصيدلي قبل تناول كوديسيران ساندوز إذا:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من مشكلات في <strong>القلب أو الكبد أو الكلى</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; خضعت مؤخرًا لعملية <strong>زرع كلى</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اضطررت<strong> </strong>إلى<strong> التقيؤ </strong>أو تقيأت مؤخرًا بشدة أو أصبت <strong>بإسهال</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من <strong>اضطراب في الغدة الكظرية</strong> يُعرف باسم متلازمة كون (تسمى أيضًا فرط الألدوستيرونية الأولي).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا <strong>بمرض السكري</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق أن عانيت من مرض يُسمى <strong>الذئبة الحمامية الجهازية</strong> (SLE).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كان لديك <strong>ضغط دم منخفض</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سبق أن عانيت من <strong>سكتة دماغية</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تعاني من <strong>حساسية</strong> أو <strong>ربو</strong>.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عانيت من أي مشكلات في <strong>التنفس أو الرئة</strong> (بما في ذلك الالتهاب أو تراكم السوائل في الرئتين) في الماضي بعد تناول هيدروكلوروثيازيد. إذا أصبت بضيق شديد في التنفس أو صعوبة في التنفس بعد تناول دواء كوديسيران ساندوز، فاستشر الطبيب على الفور.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت تتناول أيًا من الأدوية التالية لعلاج <strong>ارتفاع ضغط الدم</strong>:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد <strong>مثبطات الإنزيم المحوّل للأنجيوتنسين (</strong><strong>ACE</strong><strong>) </strong>(مثل إنالابريل، ليزينوبريل، راميبريل)، خاصةً إذا كنت تعاني من مشاكل في الكلى بسبب داء السكري</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>أليسكيرين</strong></p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كنت مصابًا <strong>بسرطان الجلد </strong>أو أُصبت به من قبل. افحص جلدك بانتظام لاكتشاف <strong>أي آفات</strong> جديدة وأبلغ طبيبك فورًا إذا أصبت بآفة جلدية غير متوقعة أثناء العلاج.</p><p dir="RTL">قد يزيد العلاج بهيدروكلوروثيازيد، وخاصةً الاستخدام طويل الأمد بجرعة عالية، من خطر الإصابة ببعض أنواع سرطان الجلد والشفاه (سرطان الجلد الأبيض). تجنب التعرض لأشعة الشمس والأشعة فوق البنفسجية أو استخدم وسيلة مناسبة للحماية من الشمس أثناء تناول كوديسيران ساندوز.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; لاحظت أن رؤيتك تزداد سوءًا أو شعرت بألم في <strong>العين</strong>. قد تكون هذه أعراض تراكم السوائل في الطبقة الوعائية للعين (الانصباب المشيمي) أو زيادة في الضغط في العين وتحدث في غضون ساعات إلى أسابيع بعد تناول كوديسيران ساندوز. إذا لم يتم علاج هذه الحالات، فقد يحدث فقدان دائم للبصر. إذا كنت تعاني من حساسية تجاه البنسلين أو السلفوناميدات من قبل، فمن المحتمل أن تعاني من هذه الحالات.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أخبري طبيبكِ إذا كنتِ تعتقدين أنك قد تكونين حاملًا (<u>أو قد تصبحين حاملًا</u>). لا يُوصى بتناول كوديسيران في مرحلة مبكرة من <strong>الحمل</strong>، ويجب عدم تناول كوديسيران إذا كنتِ حاملًا لأكثر من 3 أشهر، حيث إن تناول كوديسيران في هذه المرحلة قد يسبب ضررًا خطيرًا على الجنين (انظري قسم &quot;الحمل&quot;).</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يفحص طبيبك وظائف الكلى وضغط الدم وقيم الكهارل في الدم (مثل البوتاسيوم) على فترات منتظمة.</p><p dir="RTL">راجع أيضًا قسم &quot;لا تتناول كوديسيران ساندوز&quot;.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا انطبقت عليك إحدى الحالات المذكورة أعلاه، فقد يرغب طبيبك في رؤيتك بشكل أكثر تكرارًا وإجراء بعض الفحوصات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كنت تخطط لإجراء عملية جراحية، فيُرجى إبلاغ طبيبك أو طبيب الأسنان المتابع لك بأنك تتناول كوديسيران ساندوز. والسبب في ذلك هو أنه عند تناوله مع بعض المخدِّرات، يمكن أن يؤدي كوديسيران إلى انخفاض شديد في ضغط الدم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يتسبب كوديسيران في زيادة حساسية الجلد تجاه الشمس.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>الأطفال والمراهقون</strong></p><p dir="RTL">لا توجد تجارب حول استخدام كوديسيران لدى الأطفال والمراهقين (أقل من 18 عامًا). وبالتالي، يجب عدم إعطاء دواء كوديسيران للأطفال والمراهقين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تحدث إلى طبيبك إذا كنت <strong>رياضيًا وتشارك في فحص المنشطات</strong>، وذلك لاحتواء كوديسيران على مادة فعالة يمكن أن تؤدي إلى نتائج إيجابية أثناء فحوصات تعاطي المنشطات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول كوديسيران مع أدوية أخرى</p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول/تستخدم أو تناولت/استخدمت مؤخرًا أو قد تتناول/تستخدم أي أدوية أخرى.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يمكن أن يؤثر كوديسيران على فعالية بعض العقاقير الأخرى وقد يكون لبعض العقاقير تأثير على كوديسيران ساندوز. إذا كنت تتناول أدوية معينة أخرى، فقد يتعين على طبيبك إجراء اختبارات دم من وقت لآخر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">على وجه الخصوص، أخبر طبيبك إذا كنت تتناول أيًا من الأدوية التالية لأن طبيبك قد يحتاج إلى تعديل جرعتك و/أو اتخاذ احتياطات&nbsp;أخرى:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد مثبطات الإنزيم المحول للأنجيوتنسين (ACE) أو الأليسكيرين (انظر أيضًا قسم &quot;لا تتناول كوديسيران ساندوز&quot; وقسم &quot;تحذيرات واحتياطات&quot;)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية الأخرى التي تساعد على خفض ضغط الدم، والأدوية التي تحتوي على أليسكيرين، وديازوكسيد، ومثبطات الإنزيم المحول للأنجيوتنسين (ACE) مثل إنالابريل، أو كابتوبريل، أو ليزينوبريل، أو راميبريل</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عقاقير للتحكم في نظم القلب (عقاقير مضادة لاضطراب النظم)، مثل ديجوكسين وحاصرات بيتا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الالتهاب غير الستيرويدية (NSAIDs) مثل إيبوبروفين، أو نابروكسين، أو ديكلوفيناك، أو سيليكوكسيب، أو إيتوريكوكسيب (دواء لتقليل الألم والالتهاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حمض الأسيتيل ساليسيليك، إذا كنت تتناول أكثر من 3 جم يوميًا (دواء لتقليل الألم والالتهاب)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مستحضرات البوتاسيوم أو بدائل الملح التي تحتوي على البوتاسيوم (دواء لزيادة كمية البوتاسيوم في دمك)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هيبارين (دواء مرقق للدم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية المدرة للبول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (عقار لعلاج الاضطرابات العقلية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير التي قد تتأثر بمستويات البوتاسيوم في الدم، مثل بعض العقاقير المضادة للذهان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لخفض الكولسترول مثل كوليستيبول أو كوليسترامين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات الكالسيوم أو فيتامين د</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات الكولين، مثل أتروبين وبيبريدين</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمانتادين (لعلاج مرض باركنسون أو العداوى الخطيرة الناجمة عن الفيروسات)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الباربيتورات (نوع من المهدئات يُستخدم أيضًا لعلاج الصرع)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية لعلاج السرطان</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الستيرويدات مثل بريدنيزولون</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهرمونات النخامية (ACTH)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية السكري (أقراص أو أنسولين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الملينات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمفوتيريسين (لعلاج حالات العدوى الفطرية)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كربينوكزولون (لعلاج اضطرابات المريء أو قرح الفم)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; البنسلين أو كوتريموكسازول، المعروفان أيضًا باسم تريميثوبريم وسلفاميثوكسازول (مضاد حيوي)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السيكلوسبورين، وهو عقار يُستخدم في زراعة الأعضاء لمنع رفض الأعضاء</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; العقاقير الأخرى التي تزيد من تأثير خفض ضغط الدم، مثل باكلوفين (عقار يُستخدم لتخفيف التشنج)، أميفوستين (يُستخدم في علاج السرطان)، وبعض العقاقير المضادة للذهان</p><p dir="RTL">&nbsp;</p><p dir="RTL">تناول كوديسيران مع الطعام والشراب والكحول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; يمكنك تناول كوديسيران إما مع الطعام أو بدونه.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا وُصف لك دواء كوديسيران ساندوز، فتحدث إلى طبيبك قبل شرب أي كحول. قد يُسبب لك الكحول الشعور بالإغماء أو&nbsp;الدوار.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الحمل والرضاعة الطبيعية</p><p dir="RTL"><u>الحمل</u></p><p dir="RTL">أخبري طبيبكِ إذا كنتِ تعتقدين أنك قد تكونين حاملًا (أو قد تصبحين حاملًا). سينصحكِ طبيبكِ بشكل عام بالتوقف عن تناول كوديسيران قبل أن تصبحي حاملًا، أو بمجرد أن تعرفي أنكِ حامل، وسيوصيكِ بدواء مختلف. لا يُنصح بتناول كوديسيران في مرحلة مبكرة من الحمل، ويجب عدم تناول كوديسيران إذا كنتِ حاملًا لأكثر من 3 أشهر، لأن تناول كوديسيران في هذه المرحلة قد يسبب ضررًا خطيرًا&nbsp;للجنين.</p><p dir="RTL"><em>&nbsp;</em></p><p dir="RTL"><u>الرضاعة الطبيعية</u></p><p dir="RTL">أخبري طبيبكِ إذا كنتِ ترضعين أو ترغبين في بدء الرضاعة الطبيعية. لا يُوصى بتناول كوديسيران للأمهات المرضعات، وقد يختار طبيبكِ علاجًا آخر لكِ إذا كنتِ ترغبين في الرضاعة الطبيعية، خاصةً إذا كان طفلكِ حديث الولادة أو مولودًا قبل الأوان.</p><p dir="RTL">&nbsp;</p><p dir="RTL">القيادة واستخدام الآلات</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t75"
 coordsize="21600,21600" o:spt="75" o:preferrelative="t" path="m@4@5l@4@11@9@11@9@5xe"
 filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Title: Warndreick - Description: الرمز: Achtung" style='width:30.75pt;
 height:27pt;visibility:visible' o:gfxdata="UEsDBBQABgAIAAAAIQA0Ev94FAEAAFACAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSSy07DMBBF
90j8g+UtSpyyQAg16YLHEliUDxjsSWLhl2y3tH/PJE0kqEo33Vj2zNy5x2MvVztr2BZj0t7VfFFW
nKGTXmnX1fxj/VLcc5YyOAXGO6z5HhNfNddXy/U+YGKkdqnmfc7hQYgke7SQSh/QUab10UKmY+xE
APkFHYrbqroT0ruMLhd56MGb5RO2sDGZPe8ofCAJruPs8VA3WNVc20E/xMVJRUSTjiQQgtESMt1N
bJ064iomppKUY03qdUg3BP6Pw5D5y/TbYNK90TCjVsjeIeZXsEQupNHh00NUQkX4ptGmebMozzc9
Qe3bVktUXm4szbCcOs7Y5+0zvQ+Kcb3ceWwz+4rxPzQ/AAAA//8DAFBLAwQUAAYACAAAACEArTA/
8cEAAAAyAQAACwAAAF9yZWxzLy5yZWxzhI/NCsIwEITvgu8Q9m7TehCRpr2I4FX0AdZk2wbbJGTj
39ubi6AgeJtl2G9m6vYxjeJGka13CqqiBEFOe2Ndr+B03C3WIDihMzh6RwqexNA281l9oBFTfuLB
BhaZ4ljBkFLYSMl6oAm58IFcdjofJ0z5jL0MqC/Yk1yW5UrGTwY0X0yxNwri3lQgjs+Qk/+zfddZ
TVuvrxO59CNCmoj3vCwjMfaUFOjRhrPHaN4Wv0VV5OYgm1p+LW1eAAAA//8DAFBLAwQUAAYACAAA
ACEA79ZLcVICAADcBAAAHwAAAGNsaXBib2FyZC9kcmF3aW5ncy9kcmF3aW5nMS54bWykVMtu2zAQ
vBfoPxC825JsJbaFyIFrO0GBtDX6QM80RUlEKFIgKcVB0Fv7LT23X+P8TZd6OIZbtEB6EUju7nB2
dqiLy10hUM204UrGOBj6GDFJVcJlFuNPH68GU4yMJTIhQkkW43tm8OX85YsLEmWalDmnCBCkiUiM
c2vLyPMMzVlBzFCVTEIsVbogFrY68xJN7gC5EN7I98+9gnCJ509QK2IJqjR/BpRQ9JYlSyJrYgBS
0Oj4pOMo6P8jk0jW17r8UG60Y07f1huNeBJjUE6SAiTCXhfo0mDrnVRlTwC7VBcuX6Up2jUo9+7b
YLCdRRQOx7NgMjvDiEJoHAbn4y5O83d/qKL5+q91QKa9FBZHREpOHQ9Zbzg97S3oe4OYrTRDcJAw
Q3WM998fv+5/PH7b/4zQgua2khlGllsBSnwmWiaacXp70OQADtfdwMwMkmqZE5mxhSkZteBBlwvU
nLItk0a9Q+FW8PKKC+HIunU3W6Dyb/+ByJyylaJVwaRtTaiZIBbcb3JeGox0xIotg3nq10nQmBOm
cGOsu87No7Hnw2i68P3Z6NVgeeYvB6E/WQ8Ws3AymPjrSeiH02AZLL+46iCMKsOgUyJWJe/fShD+
xrbgVCujUjukqvBaov17AaKB374WVBPR+QNkAUKNVj1FOHKSOK7GamZp7pYpqPUetG11PQS65F5L
A45G27s3KoHJkcqqpvnn2xPg++JSG3vNVIHcApQFLg04qUHYllWf4vhK5Th1bJt3BljgF2j15F03
zXf/IffzON7PfwEAAP//AwBQSwMECgAAAAAAAAAhAPAsTkHjAwAA4wMAABoAAABjbGlwYm9hcmQv
bWVkaWEvaW1hZ2UxLnBuZ4lQTkcNChoKAAAADUlIRFIAAAApAAAAJAgGAAAAFP4TKAAAAAFzUkdC
AkDAfcUAAAAJcEhZcwAADsQAAA7EAZUrDhsAAAAZdEVYdFNvZnR3YXJlAE1pY3Jvc29mdCBPZmZp
Y2V/7TVxAAADY0lEQVRYw9WYP2gaURzHRRL/k6hkUAhEyaBLQBzERYgQiDhIwUB00C1Zgi4KGTKk
mRQcAl0El1DpXMd0akan4uhW6eTS1qaUCs3w+r5H3vF8ufPuTKrXLzw479/73M/f7/t7d5arqyuL
2YfpAV8UslQqZaxW6wNGsVjMmQ7y/Pzca7fbJxaLhWDYbLaftVotZCrIeDzeQQQZJN3+s7u7+8E0
kKenpzEaxR8MkA3swzFTQG5vb/dFQDa8Xu/nlUMeHx+/4qPodrtJKpUi6+vrLJrf8/l8aWWQzWbT
4fF4xjzg5eUlGY/HZGNjQ46m0+n8hnNXArm/v/+aRuwXg/H7/WQ6nRIIsIDG/rW1tWkikXizdEhq
OQH6V94zwM3NTdLr9QgTYAHNFdE9rlkqJOwFNsMgotGoBHd7e0va7ba03e12ic/nk0FDodDHpUFS
W0nyxo0oDgYDCYrmKHE4HCSXy0mg4XCYj+YE1y4FErbCJkYVHx4eSkBbW1tEBO/3+7ChZ1uSoZMz
mUwFLY9NiipGNYtRA9jd3Z20P51OE75d4h7/DBI2AjthE+Kvpf1ZLpZkMkl4+OFwKO0fjUYz0VzE
khbuz7zlQEdHRzKIy+WSIwydnJzAilhff8C9XhyyWq1G+SiialEovOr1+kxL5KVgSRMjqyRdJ8E+
eADkn6hGoyFHC0UkqtVqyQZv1JIM92dWuaJubm6kPFV7CCVLwkL52ZBIcAr1RclyRKGaWYGgiJSE
roSHNGpJcw8eHBzU+f7MW44oRJcBoIjUxFsS7o05FoYU+7NoOaIAj6rGuSgiNfEP83jfsVZfVz2w
t7f3ju/PouUo6THXyPX19dzzjFqSrlcCPHmn0yFaQjpQq5KKaJ4U1pxf571qKO6kFjLUshwlRSIR
srOzo5q3i1rSkx1Y7mPZz/dhLBS0NJlMpFzMZrOKFiUKqRMIBGZe3GB3mpBif8ZANepRuVyWr1Ey
cz2WBLtT6uszP7DMx3Jfj+WIisVi8mRYU2oVGRMWzFqWJG+gl/KLWUxUqVSIXiEqqFg8WKFQ0H2d
aEkoItGSVPszBl6ojIyLiwtydnZm+Dr2CqxmSfLHJj6Kqx7i148nrwRmGTTH385A0uR9T/Ppt1kA
wcIXkPzpLhgMfjILJHKSt6L/4kvvX9E1PiYojjxCAAAAAElFTkSuQmCCUEsDBBQABgAIAAAAIQCc
Tl4h4gYAADocAAAaAAAAY2xpcGJvYXJkL3RoZW1lL3RoZW1lMS54bWzsWU9vG0UUvyPxHUZ7b+P/
jaM6VezYDbRpo9gt6nG8Hu9OM7uzmhkn9Q21RyQkREEcqMSNAwIqtRKX8mkCRVCkfgXezOyud+I1
SdsIKmgO8e7b37z/782b3ctX7kUMHRIhKY87XvVixUMk9vmExkHHuzUaXFj3kFQ4nmDGY9Lx5kR6
Vzbff+8y3vAZTcYci8koJBFBwCiWG7jjhUolG2tr0gcylhd5QmJ4NuUiwgpuRbA2EfgIBERsrVap
tNYiTGNvEzgqzajP4F+spCb4TAw1G4JiHIH0m9Mp9YnBTg6qGiHnsscEOsSs4wHPCT8akXvKQwxL
BQ86XsX8eWubl9fwRrqIqRVrC+sG5i9dly6YHNSMTBGMc6HVQaN9aTvnbwBMLeP6/X6vX835GQD2
fbDU6lLk2RisV7sZzwLIXi7z7lWalYaLL/CvL+nc7na7zXaqi2VqQPaysYRfr7QaWzUHb0AW31zC
N7pbvV7LwRuQxbeW8INL7VbDxRtQyGh8sITWAR0MUu45ZMrZTil8HeDrlRS+QEE25NmlRUx5rFbl
WoTvcjEAgAYyrGiM1DwhU+xDTvZwNBYUawF4g+DCE0vy5RJJy0LSFzRRHe/DBMdeAfLy2fcvnz1B
x/efHt//6fjBg+P7P1pGzqodHAfFVS++/ezPRx+jP5588+LhF+V4WcT/+sMnv/z8eTkQymdh3vMv
H//29PHzrz79/buHJfAtgcdF+IhGRKIb5Ajt8wgMM15xNSdj8WorRiGmxRVbcSBxjLWUEv59FTro
G3PM0ug4enSJ68HbAtpHGfDq7K6j8DAUM0VLJF8LIwe4yznrclHqhWtaVsHNo1kclAsXsyJuH+PD
Mtk9HDvx7c8S6JtZWjqG90LiqLnHcKxwQGKikH7GDwgpse4OpY5fd6kvuORThe5Q1MW01CUjOnay
abFoh0YQl3mZzRBvxze7t1GXszKrt8mhi4SqwKxE+RFhjhuv4pnCURnLEY5Y0eHXsQrLlBzOhV/E
9aWCSAeEcdSfECnL1twUYG8h6NcwdKzSsO+yeeQihaIHZTyvY86LyG1+0AtxlJRhhzQOi9gP5AGk
KEZ7XJXBd7lbIfoe4oDjleG+TYkT7tO7wS0aOCotEkQ/mYmSWF4l3Mnf4ZxNMTGtBpq606sjGv9d
42YUOreVcH6NG1rl868flej9trbsLdi9ympm50SjXoU72Z57XEzo29+dt/Es3iNQEMtb1Lvm/K45
e//55ryqns+/JS+6MDRoPYvYQduM3dHKqXtKGRuqOSPXpRm8Jew9kwEQ9TpzuiT5KSwJ4VJXMghw
cIHAZg0SXH1EVTgMcQJDe9XTTAKZsg4kSriEw6Ihl/LWeBj8lT1qNvUhxHYOidUun1hyXZOzs0bO
xmgVmANtJqiuGZxVWP1SyhRsex1hVa3UmaVVjWqmKTrScpO1i82hHFyemwbE3Jsw1CAYhcDLLTjf
a9Fw2MGMTLTfbYyysJgonGeIZIgnJI2Rtns5RlUTpCxXlgzRdthk0AfHU7xWkNbWbN9A2lmCVBTX
WCEui96bRCnL4EWUgNvJcmRxsThZjI46XrtZa3rIx0nHm8I5GS6jBKIu9RyJWQBvmHwlbNqfWsym
yhfRbGeGuUVQhVcf1u9LBjt9IBFSbWMZ2tQwj9IUYLGWZPWvNcGt52VASTc6mxb1dUiGf00L8KMb
WjKdEl8Vg12gaN/Z27SV8pkiYhhOjtCYzcQ+hvDrVAV7JlTC6w7TEfQNvJvT3jaP3OacFl3xjZjB
WTpmSYjTdqtLNKtkCzcNKdfB3BXUA9tKdTfGvboppuTPyZRiGv/PTNH7Cbx9qE90BHx40Ssw0pXS
8bhQIYculITUHwgYHEzvgGyB97vwGJIK3kqbX0EO9a+tOcvDlDUcItU+DZCgsB+pUBCyB23JZN8p
zKrp3mVZspSRyaiCujKxao/JIWEj3QNbem/3UAipbrpJ2gYM7mT+ufdpBY0DPeQU683pZPnea2vg
n558bDGDUW4fNgNN5v9cxXw8WOyqdr1Znu29RUP0g8WY1ciqAoQVtoJ2WvavqcIrbrW2Yy1ZXGtm
ykEUly0GYj4QJfAOCel/sP9R4TP7BUNvqCO+D70VwccLzQzSBrL6gh08kG6QljiGwckSbTJpVta1
6eikvZZt1uc86eZyTzhba3aWeL+is/PhzBXn1OJ5Ojv1sONrS1vpaojsyRIF0jQ7yJjAlH3J2sUJ
GgfVjgdfkyDQ9+AKvkd5QKtpWk3T4Ao+MsGwZL8Mdbz0IqPAc0vJMfWMUs8wjYzSyCjNjALDWfoN
JqO0oFPpzybw2U7/eCj7QgITXPpFJWuqzue+zb8AAAD//wMAUEsDBBQABgAIAAAAIQBTUolh0gAA
AKsBAAAqAAAAY2xpcGJvYXJkL2RyYXdpbmdzL19yZWxzL2RyYXdpbmcxLnhtbC5yZWxzrJDBSgQx
DIbvgu9QcreZ2YOIbGcvIuxV1gcIbaZTnKalreK+vdW9OLDgxUsgCfny8e8Pn3FVH1xqSGJg1AMo
FptcEG/g9fR89wCqNhJHaxI2cOYKh+n2Zv/CK7V+VJeQq+oUqQaW1vIjYrULR6o6ZZa+mVOJ1Hpb
PGayb+QZd8Nwj+U3A6YNUx2dgXJ0O1Cnc+6f/2aneQ6Wn5J9jyztygts3Ys7kIrnZkDry+RSR91d
Aa9rjP+pEWKPYKMR2QXCn/mos/hvDdxEPH0BAAD//wMAUEsBAi0AFAAGAAgAAAAhADQS/3gUAQAA
UAIAABMAAAAAAAAAAAAAAAAAAAAAAFtDb250ZW50X1R5cGVzXS54bWxQSwECLQAUAAYACAAAACEA
rTA/8cEAAAAyAQAACwAAAAAAAAAAAAAAAABFAQAAX3JlbHMvLnJlbHNQSwECLQAUAAYACAAAACEA
79ZLcVICAADcBAAAHwAAAAAAAAAAAAAAAAAvAgAAY2xpcGJvYXJkL2RyYXdpbmdzL2RyYXdpbmcx
LnhtbFBLAQItAAoAAAAAAAAAIQDwLE5B4wMAAOMDAAAaAAAAAAAAAAAAAAAAAL4EAABjbGlwYm9h
cmQvbWVkaWEvaW1hZ2UxLnBuZ1BLAQItABQABgAIAAAAIQCcTl4h4gYAADocAAAaAAAAAAAAAAAA
AAAAANkIAABjbGlwYm9hcmQvdGhlbWUvdGhlbWUxLnhtbFBLAQItABQABgAIAAAAIQBTUolh0gAA
AKsBAAAqAAAAAAAAAAAAAAAAAPMPAABjbGlwYm9hcmQvZHJhd2luZ3MvX3JlbHMvZHJhd2luZzEu
eG1sLnJlbHNQSwUGAAAAAAYABgCvAQAADREAAAAA
">
 <v:imagedata src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.png"
  o:title="" cropright="-320f"/>
</v:shape><![endif]--><img width="41" height="36" alt="Title: Warndreick - Description: الرمز: Achtung" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" />&nbsp;انتبه: قد يضعف هذا الدواء القدرة على التفاعل والقدرة على القيادة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">قد يشعر بعض الأشخاص بالتعب أو الدوار عند تناول كوديسيران ساندوز. إذا كان هذا هو الحال معك، فلا تقود السيارة ولا تشغل أي أدوات أو آلات.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كوديسيران على اللاكتوز</p><p dir="RTL">يُرجى عدم تناول كوديسيران إلا بعد استشارة طبيبك إذا كنت تعلم أنك تعاني من عدم تحمل أنواع معينة من السكر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يحتوي كوديسيران على الصوديوم.</p><p dir="RTL">يحتوي هذا الدواء على أقل من 1 مليمول من الصوديوم (23 ملغ) لكل قرص، أي أنه &quot;خالٍ من الصوديوم&quot; تقريبًا.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائمًا وفقًا لتوجيهات الطبيب المتابع لك أو الصيدلي. استشر الطبيب المتابع لك أو الصيدلي إذا لم تكن متأكدًا. من المهم تناول كانديسارتان/ساندوز HTC كل يوم.</p><p dir="RTL">&nbsp;</p><p dir="RTL">الجرعة المعتادة من كوديسيران هي قرص واحد يوميًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">ابتلع القرص مع الماء.</p><p dir="RTL">حاول تناول القرص في نفس الوقت كل يوم. سيساعدك ذلك على تذكر تناوله.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا تناولت جرعة من كوديسيران أكثر مما ينبغي</p><p dir="RTL">إذا كنت قد تناولت كمية من كوديسيران أكبر مما وصفه لك طبيبك، فيُرجى استشارة طبيبك أو الصيدلي على الفور للحصول على المشورة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا نسيت تناول كوديسيران ساندوز</p><p dir="RTL">لا تتناول جرعة مضاعفة لتعويض الجرعة المنسية. فقط تناول الجرعة التالية كالمعتاد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا توقفت عن تناول كوديسيران ساندوز</p><p dir="RTL">إذا توقفت عن استخدام كوديسيران ساندوز، فقد يعود ضغط الدم للارتفاع مرة أخرى. لذلك، لا تتوقف عن تناول كوديسيران من دون استشارة طبيبك أولًا.</p><p dir="RTL">&nbsp;</p><p dir="RTL">إذا كانت لديك أيّ أسئلة أخرى حول استخدام هذا الدواء، فاسأل طبيبك أو الصيدلي.</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، يمكن أن يسبب هذا الدواء آثارًا جانبية، على الرغم من أنها لا تصيب الجميع. من المهم أن تكون على دراية بهذه الآثار الجانبية المحتملة. بعض الآثار الجانبية للكوديسيران تحدث بسبب سيليكسيتيل الكانديسارتان وبعضها بسبب هيدروكلوروثيازيد.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>لا تستمر في تناول كوديسيران واستشر طبيبًا على الفور إذا عانيت من أحد ردود الفعل التحسسية التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس مع أو بدون تورم في الوجه و/أو الشفتين و/أو اللسان و/أو الحلق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم في الوجه و/أو الشفتين و/أو اللسان و/أو الحلق مما قد يسبب صعوبة في البلع.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; حكة خطيرة في الجلد (مع تورمات تشبه البثور).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>توقف أيضًا عن تناول كوديسيران واستشر طبيبًا على الفور إذا أصبت</strong> بضيق حاد في التنفس (العلامات هي ضيق شديد في التنفس، وحمى، وضعف، وارتباك). يعد هذا أثرًا جانبيًا نادرًا جدًا (قد يصيب ما يصل إلى شخص واحد من كل 10000 شخص يخضعون للعلاج)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">يمكن أن يؤدي كوديسيران إلى انخفاض عدد خلايا الدم البيضاء. قد تقل مقاومتك للعداوى وقد تشعر بالتعب أو تُصاب بعدوى أو حمى. إذا حدث ذلك، فاستشر طبيبك. قد يُجري طبيبك اختبارات دم من حين لآخر للتحقق مما إذا كان للكوديسيران تأثير سابق على دمك (ندرة&nbsp;المحببات).</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>تشمل الآثار الجانبية المحتملة الأخرى ما يلي:</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>شائعة</strong> (قد تؤثر على ما يصل إلى شخص واحد من كل 10 أشخاص يخضعون للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التغير في نتائج اختبار الدم:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض كمية الصوديوم في الدم. في الحالات الخطيرة، قد تشعر بالضعف أو نقص الطاقة أو تشنجات عضلية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة أو انخفاض كمية البوتاسيوم في دمك، خاصةً إذا كنت تعاني سابقًا من مشاكل في الكلى أو قصور في القلب. في الحالات الخطيرة، قد تعاني من التعب أو الضعف أو عدم انتظام ضربات القلب أو الشعور بالوخز (&quot;التنمل&quot;).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; زيادة نسبة الكولسترول أو السكر أو حمض اليوريك في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سكر في البول</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الدوخة/الشعور بالدوران أو الضعف</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الصداع</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عدوى الجهاز التنفسي</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>غير شائعة</strong> (قد تؤثر على ما يصل إلى 1 من كل 100 شخص يخضعون للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض ضغط الدم. قد يُسبب لك هذا الشعور بالإغماء أو الدوار.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; فقدان الشهية، الإسهال، الإمساك، تهيج المعدة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الطفح الجلدي، الشرى، الطفح الجلدي الناجم عن الحساسية لأشعة الشمس</p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>نادرة</strong> (قد تؤثر على ما يصل إلى 1 من كل 1000 شخص يخضعون للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اصفرار الجلد أو بياض العينين (اليرقان). إذا كان هذا ينطبق عليك، فأخبر طبيبك على الفور</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد تتأثر وظائف الكلى لديك، خاصةً إذا كنت تعاني من مشكلات في الكلى أو قصور في القلب</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة النوم، الاكتئاب، التململ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; وخز أو حكة في ذراعيك أو ساقيك</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تشوش الرؤية على مدى فترة زمنية قصيرة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضربات قلب غير طبيعية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; صعوبة في التنفس (بما في ذلك الالتهاب الرئوي والسوائل في الرئتين)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ارتفاع درجة الحرارة (الحمى)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التهاب البنكرياس. يسبب ذلك ألمًا في المعدة يتراوح من متوسط إلى شديد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; التشنجات العضلية</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تلف الأوعية الدموية مما يسبب ظهور بقع حمراء أو أرجوانية في الجلد</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; انخفاض في عدد خلايا الدم الحمراء أو البيضاء أو الصفائح الدموية. قد تشعر بالتعب أو تصاب بعدوى أو حمى أو كدمات خفيفة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; طفح جلدي كبير سريع التطور، مع تقرح أو تقشر الجلد وربما تقرح في الفم</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>نادرة جدًا</strong> (قد تصيب حتى 1 من كل 10000 شخص يخضعون للعلاج)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تورم الوجه و/أو الشفتين و/أو اللسان و/أو الحلق</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحكة</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ألم في الظهر، ألم في المفاصل والعضلات</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تغيرات في وظائف الكبد، بما في ذلك التهاب الكبد. قد تلاحظ التعب، وقد يظهر على جلدك وبياض عينيك لون أصفر أو قد تظهر عليك أعراض تشبه أعراض الأنفلونزا</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; السعال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الغثيان</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>غير معروفة</strong> (لا يمكن تقدير معدل التكرار من البيانات المتاحة)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصر النظر المفاجئ</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ضعف في الرؤية أو ألم في عينيك بسبب ارتفاع الضغط (علامات محتملة لتراكم السوائل في الطبقة الوعائية من العين (الانصباب المشيمي) أو زرق انسداد الزاوية الحاد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة الحمامية الجهازية والجلدية (حالة تحسسية مع حمى وألم في المفاصل وطفح جلدي، والتي قد يصاحبها أيضًا احمرار، وبثور، وتقشير، وتكوّن عقدة في الجلد)</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الإسهال</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سرطان الجلد والشفاه (سرطان الجلد غير الميلانيني)</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL">&nbsp;</p><p dir="RTL"><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong><strong>للإبلاغ عن أيّ أثر (آثار) جانبي)</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; المملكة العربية السعودية</p><p dir="RTL"><!--[if gte vml 1]><v:shapetype id="_x0000_t202"
 coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_16" o:spid="_x0000_s1028"
 type="#_x0000_t202" style='position:absolute;left:0;text-align:left;
 margin-left:0;margin-top:11.3pt;width:429pt;height:104.9pt;z-index:251659264;
 visibility:visible;mso-wrap-style:square;mso-width-percent:0;
 mso-height-percent:0;mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
 mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
 mso-position-horizontal:left;mso-position-horizontal-relative:margin;
 mso-position-vertical:absolute;mso-position-vertical-relative:text;
 mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
 mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoPlainText dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=LTR style='font-size:11.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial'><span style='mso-spacerun:yes'> </span></span><span
    lang=AR-SA style='font-size:11.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial'>معلومات الاتصال بشركة </span><span dir=LTR
    style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>NPC</span><span dir=RTL></span><span lang=AR-SA style='font-size:
    11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial'><span
    dir=RTL></span> في المملكة العربية السعودية:</span><span dir=LTR
    style='font-size:11.0pt;font-family:"Arial",sans-serif;layout-grid-mode:
    line'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span dir=LTR style='font-size:11.0pt;font-family:"Arial",sans-serif;
    layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-right:.5in;text-align:right;
    text-indent:-.25in;mso-list:l0 level1 lfo9;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";layout-grid-mode:line'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>المركز الوطني للتيقظ والسلامة الدوائية (</span><span dir=LTR
    style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>NPC</span><span dir=RTL></span><span lang=AR-SA style='font-size:
    11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial'><span
    dir=RTL></span>):</span><span dir=LTR style='font-size:11.0pt;font-family:
    "Arial",sans-serif;layout-grid-mode:line'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-right:.5in;text-align:right;
    text-indent:-.25in;mso-list:l0 level1 lfo9;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";layout-grid-mode:line'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>مركز اتصال الهيئة العامة للغذاء والدواء: 19999</span><span
    lang=AR-SA style='font-size:11.0pt;font-family:"Arial",sans-serif;
    layout-grid-mode:line'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-right:.5in;text-align:right;
    text-indent:-.25in;mso-list:l0 level1 lfo9;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";layout-grid-mode:line'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>البريد الإلكتروني: </span><a href="mailto:npc.drug@sfda.gov.sa"><span
    dir=LTR style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial;color:windowtext;text-decoration:none;text-underline:none'>npc.drug@sfda.gov.sa</span></a><span
    dir=LTR style='font-size:11.0pt;font-family:"Arial",sans-serif;layout-grid-mode:
    line'><o:p></o:p></span></p>
    <p class=MsoPlainText dir=RTL style='margin-right:.5in;text-align:right;
    text-indent:-.25in;mso-list:l0 level1 lfo9;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    style='font-size:11.0pt;font-family:"Courier New";mso-fareast-font-family:
    "Courier New";layout-grid-mode:line'><span style='mso-list:Ignore'>o<span
    style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>الموقع الإلكتروني: </span><span dir=LTR style='font-size:11.0pt;
    font-family:"Arial",sans-serif;mso-fareast-font-family:Arial'>ade.sfda.gov.sa</span><span
    dir=LTR style='font-size:11.0pt;font-family:"Arial",sans-serif;layout-grid-mode:
    line'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span lang=DE dir=LTR style='mso-bidi-font-size:11.0pt;
    font-family:"Arial",sans-serif;layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><v:shape id="Text_x0020_Box_x0020_4" o:spid="_x0000_s1027" type="#_x0000_t202"
 style='position:absolute;left:0;text-align:left;margin-left:.3pt;margin-top:126.6pt;
 width:429pt;height:89.25pt;z-index:251663360;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoNormal dir=RTL style='margin-top:2.0pt;margin-right:0in;
    margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;text-align:right;
    line-height:12.6pt;text-autospace:none;direction:rtl;unicode-bidi:embed'><span
    lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial'>قسم سلامة المرضى بشركة </span><span
    lang=AR-EG style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
    mso-fareast-font-family:Arial;mso-bidi-language:AR-EG'>نوفارتيس كونسالتينج
    أيه جي </span><span lang=AR-SA style='mso-bidi-font-size:11.0pt;font-family:
    "Arial",sans-serif;mso-fareast-font-family:Arial'>- المملكة العربية
    السعودية:</span><span lang=DE dir=LTR style='mso-bidi-font-size:11.0pt;
    font-family:"Arial",sans-serif;layout-grid-mode:line'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpFirst dir=RTL style='margin-top:2.0pt;
    margin-right:.25in;margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:12.6pt;mso-list:l4 level1 lfo8;
    text-autospace:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
    mso-fareast-font-family:"Courier New";layout-grid-mode:line'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>الرقم المجاني: 8001240078</span><span lang=AR-SA style='mso-bidi-font-size:
    11.0pt;font-family:"Arial",sans-serif;layout-grid-mode:line'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:2.0pt;
    margin-right:.25in;margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:12.6pt;mso-list:l4 level1 lfo8;
    text-autospace:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
    mso-fareast-font-family:"Courier New";layout-grid-mode:line'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>الهاتف: </span><span dir=LTR></span><span lang=DE dir=LTR
    style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'><span dir=LTR></span>+966112658100</span><span lang=AR-SA
    style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;layout-grid-mode:
    line'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpMiddle dir=RTL style='margin-top:2.0pt;
    margin-right:.25in;margin-bottom:2.0pt;margin-left:0in;mso-add-space:auto;
    text-align:right;text-indent:-.25in;line-height:12.6pt;mso-list:l4 level1 lfo8;
    text-autospace:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
    mso-fareast-font-family:"Courier New";layout-grid-mode:line'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>فاكس: </span><span dir=LTR></span><span lang=DE dir=LTR
    style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'><span dir=LTR></span>+966112658107</span><span lang=DE dir=LTR
    style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;layout-grid-mode:
    line'><o:p></o:p></span></p>
    <p class=MsoListParagraphCxSpLast dir=RTL style='margin-top:0in;margin-right:
    .25in;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;mso-add-space:
    auto;text-align:right;text-indent:-.25in;mso-list:l4 level1 lfo8;
    text-autospace:none;direction:rtl;unicode-bidi:embed'><![if !supportLists]><span
    lang=DE style='mso-bidi-font-size:11.0pt;font-family:"Courier New";
    mso-fareast-font-family:"Courier New";layout-grid-mode:line'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
    style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:
    Arial'>البريد الإلكتروني: </span><span lang=DE dir=LTR style='mso-bidi-font-size:
    11.0pt;font-family:"Arial",sans-serif;mso-fareast-font-family:Arial'>adverse.events@novartis.com</span><span
    lang=DE dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
    layout-grid-mode:line'><o:p></o:p></span></p>
    <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
    unicode-bidi:embed'><span lang=DE dir=LTR style='mso-bidi-font-size:11.0pt;
    font-family:"Arial",sans-serif;layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="146" alt="Text Box:  معلومات الاتصال بشركة NPC في المملكة العربية السعودية:

o	المركز الوطني للتيقظ والسلامة الدوائية (NPC):
o	مركز اتصال الهيئة العامة للغذاء والدواء: 19999
o	البريد الإلكتروني: npc.drug@sfda.gov.sa
o	الموقع الإلكتروني: ade.sfda.gov.sa

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /></td></tr><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td style="vertical-align:top"><img width="578" height="125" alt="Text Box: قسم سلامة المرضى بشركة نوفارتيس كونسالتينج أيه جي - المملكة العربية السعودية:
o	الرقم المجاني: 8001240078
o	الهاتف: +966112658100
o	فاكس: +966112658107
o	البريد الإلكتروني: adverse.events@novartis.com

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image002.gif" /></td></tr></tbody></table><p>&nbsp;</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><p dir="RTL">&nbsp;</p><ul><br /><li dir="RTL"><strong>دول مجلس التعاون الخليجي الأخرى</strong></li><li dir="RTL"><!--[if gte vml 1]><v:shape id="Text_x0020_Box_x0020_15"
      o:spid="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
      left:0;text-align:left;margin-left:0;margin-top:3.5pt;width:429pt;
      height:23.25pt;text-indent:0;z-index:251661312;visibility:visible;
      mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
      mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;
      mso-wrap-distance-right:9pt;mso-wrap-distance-bottom:0;
      mso-position-horizontal:absolute;mso-position-horizontal-relative:margin;
      mso-position-vertical:absolute;mso-position-vertical-relative:text;
      mso-width-percent:0;mso-height-percent:0;mso-width-relative:margin;
      mso-height-relative:margin;v-text-anchor:top' o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
      <v:textbox>
       <![if !mso]>
       <table cellpadding=0 cellspacing=0 width="100%">
        <tr>
         <td><![endif]>
         <div>
         <p class=MsoListParagraph dir=RTL style='margin-top:0in;margin-right:
         .5in;margin-bottom:0in;margin-left:0in;margin-bottom:.0001pt;
         mso-add-space:auto;text-align:right;text-indent:-.25in;mso-list:l5 level1 lfo7;
         mso-layout-grid-align:none;text-autospace:none;direction:rtl;
         unicode-bidi:embed'><![if !supportLists]><span lang=DE
         style='font-size:12.0pt;mso-bidi-font-size:11.0pt;layout-grid-mode:
         line'><span style='mso-list:Ignore'>-<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
         </span></span></span><![endif]><span dir=RTL></span><span lang=AR-SA
         style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
         mso-fareast-font-family:Arial'>يُرجى الاتصال بالسلطة المختصة ذات
         الصلة.</span><span dir=LTR></span><span lang=AR-SA dir=LTR
         style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
         mso-fareast-font-family:Arial'><span dir=LTR></span> </span><span
         lang=DE dir=LTR style='mso-bidi-font-size:11.0pt;font-family:"Arial",sans-serif;
         layout-grid-mode:line'><o:p></o:p></span></p>
         <p class=Default dir=RTL style='text-align:right;direction:rtl;
         unicode-bidi:embed'><span lang=DE-AT dir=LTR style='font-size:11.0pt;
         font-family:"Arial",sans-serif;color:windowtext;layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
         <p class=MsoNormal dir=RTL style='text-align:right;direction:rtl;
         unicode-bidi:embed'><span lang=DE dir=LTR style='mso-bidi-font-size:
         11.0pt;font-family:"Arial",sans-serif;layout-grid-mode:line'><o:p>&nbsp;</o:p></span></p>
         </div>
         <![if !mso]></td>
        </tr>
       </table>
       <![endif]></v:textbox>
      <w:wrap anchorx="margin"/>
     </v:shape><![endif]--><img width="578" height="37" alt="Text Box: -	يُرجى الاتصال بالسلطة المختصة ذات الصلة. 


" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image003.gif" />&nbsp;</li></ul><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">احفظ هذا الدواء بعيدًا عن مرأى ومتناول الأطفال.</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تستخدم هذا الدواء بعد تاريخ انتهاء الصلاحية المذكور على الكرتون وعلى الزجاجة/الشريط بعد كلمة &quot;EXP&quot;. يشير تاريخ انتهاء الصلاحية إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL">&nbsp;</p><p dir="RTL">يُحفظ في درجة حرارة أقل من 30 درجة مئوية. يُحفظ في العبوة الأصلية لحمايته من الرطوبة.</p><p dir="RTL">&nbsp;</p><p dir="RTL">مدة الصلاحية 24 شهرًا</p><p dir="RTL">&nbsp;</p><p dir="RTL">لا تتخلص من أيّة أدوية عبر مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد تستخدمها. ستساعد هذه الإجراءات على حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما الذي يحتوي عليه كوديسيران</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المواد الفعالة هي سيليكسيتيل الكانديسارتان وهيدروكلوروثيازيد.</p><p dir="RTL">.</p><p dir="RTL"><strong><u>كوديسيران 16 مجم/12.5 مجم:</u></strong></p><p dir="RTL">يحتوي كل قرص على 16 ملغ سيليكسيتيل الكانديسارتان و12.5 ملغ هيدروكلوروثيازيد.</p><p dir="RTL">&nbsp;</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; المكونات الأخرى هي:</p><p dir="RTL">أحادي هيدرات اللاكتوز (انظر القسم الأخير 2)، نشا الذرة، بوفيدون</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><u>كوديسيران 16 مجم/12.5 مجم:</u></p><p dir="RTL">أقراص تُشبه المشمش، رخامية، بيضاوية الشكل، محدبة الوجهين، مع خط محزز على كلا الجانبين.</p><p dir="RTL">&nbsp;</p><p dir="RTL">وهذا الخط هو فقط لتسهيل كسر القرص لسهولة البلع وليس لتقسيمه إلى جرعات متساوية.</p><p dir="RTL">&nbsp;</p><p dir="RTL"><u>أحجام العبوا</u><u>ت:</u></p><p dir="RTL">شريط من الألومنيوم/الألومنيوم مع مادة مجففة: 28 قرصًا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>مالك حق التَّسويق</strong></p><p dir="RTL">شركة ساندوز المحدودة</p><p dir="RTL">بيوكيميستريز 10، 6250 كوندل، النمسا</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>جهة التَّصنيع</strong></p><p dir="RTL">شركة ليك للصناعات الدَّوائية شركة مساهمة</p><p dir="RTL">فيروفسكوفا 57، 1526 ليوبليانا، سلوفينيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            مايو 2022.
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                CoDiCERAN 16 mg/12.5 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Codiceran 16 mg/12.5 mg – tablets
1 tablet contains 16 mg candesartan cilexetil and 12.5 mg hydrochlorothiazide
Excipients with known effect:
Each tablet contains 72.1 mg lactose (as lactose monohydrate) and 0.003 mg (0.0001 mmol) sodium.

For the full list of excipients, see Section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet

Codiceran 16 mg/12.5 mg – tablets
Apricot, marbled, oval, biconvex tablets, with a score line on both sides.


The score line is only to divide the tablet for ease of swallowing and not to divide it into equal doses.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Codiceran is indicated for:</p><p>&nbsp;</p><p>Treatment of primary hypertension in adult patients whose blood pressure cannot be optimally controlled with candesartan cilexetil or hydrochlorothiazide monotherapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology</u></p><p>The recommended dose of Codiceran is one tablet once daily.</p><p>&nbsp;</p><p>Dose titration of the respective components (candesartan cilexetil and hydrochlorothiazide) is recommended. If clinically indicated, a direct switch from monotherapy to Codiceran may be considered. Dose titration of candesartan cilexetil is recommended when switching from hydrochlorothiazide monotherapy. Codiceran can be used in patients whose blood pressure cannot be optimally controlled with candesartan cilexetil or hydrochlorothiazide monotherapy or Codiceran at a lower dose.</p><p>&nbsp;</p><p>Within 4&nbsp;weeks of starting treatment, most of the antihypertensive effect is usually achieved.</p><p>&nbsp;</p><p><u>Special populations</u></p><p>&nbsp;</p><p><em>Elderly patients</em></p><p>No dose adjustment is required for elderly female patients.</p><p>&nbsp;</p><p><em>Intravascular volume depletion</em></p><p>For patients at risk of hypotension, such as Patients with suspected volume depletion, dose titration of candesartan cilexetil is recommended (a starting dose of 4&nbsp;mg candesartan cilexetil may be considered in these patients).</p><p>&nbsp;</p><p><em>Impaired renal function</em></p><p>In patients with mild to moderate renal impairment (creatinine clearance &ge;30-80&nbsp;ml/min/1.73&nbsp;m<sup>2</sup> body surface area (BSA)) a dose titration of [<em>sic</em>] is recommended. Codiceran is contraindicated in patients with severely impaired renal function (creatinine clearance &lt;30&nbsp;ml/min/1.73&nbsp;m<sup>2</sup> BSA) (see Section 4.3).</p><p><em>&nbsp;</em></p><p><em>Impaired liver function</em></p><p>Dose adjustment is not recommended in patients with mild to moderate chronic hepatic impairment.</p><p>Codiceran is contraindicated in patients with seriously reduced liver function and/or cholestasis (see Section 4.3).</p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety and efficacy of Codiceran in children and adolescents between birth and 18&nbsp;years has not been established. No data is available.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p>For oral use.</p><p>Codiceran can be taken with or without food.</p><p>The bio-availability of candesartan is not affected by the intake of food.</p><p>There is no clinically significant interaction between hydrochlorothiazide and food.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                •	Hypersensitivity to the active substances or to any of the excipients or to sulfonamide-derived active substances. Hydrochlorothiazide is a sulfonamide-derived active substance.
•	Second and third trimester of pregnancy (see Sections 4.4 and 4.6).
•	Severe impairment of renal function (creatinine clearance <30 ml/min/1.73 m2 BSA).
•	Serious impairment of liver function and/or cholestasis.
•	Treatment-resistant hypokalaemia or hypercalcaemia.
•	Gout
•	The concomitant use of Codiceran and medicines containing aliskiren is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 ml/min/1.73 m²) (see Sections 4.5 and 5.1).

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</em></p><p>There is evidence to show that concomitant use of ACE inhibitors, angiotensin&nbsp;II receptor antagonists or aliskiren increases the risk of hypotension, hyperkalaemia and reduced renal function (including an acute renal failure). Dual blockade of the RAAS by concomitant use of ACE inhibitors, angiotensin&nbsp;II receptor antagonists or aliskiren is hence not recommended (see Sections 4.5 and 5.1).</p><p>If treatment with a dual blockade is considered to be absolutely necessary, this should be administered only under the supervision of a specialist and while conducting regular tests for the renal function, electrolyte values and blood pressure.</p><p>ACE inhibitors and angiotensin&nbsp;II receptor antagonists should not be used concomitantly in patients suffering from diabetic nephropathy.</p><p><em>&nbsp;</em></p><p><em>Impaired renal function</em></p><p>As with other substances that inhibit the renin-angiotensin-aldosterone system, renal function changes may occur in sensitive patients treated with Codiceran (see Section&nbsp;4.3).</p><p><em>&nbsp;</em></p><p><em>Kidney transplantation</em></p><p>There is limited clinical data on the use of Codiceran in patients who have recently undergone a kidney transplant.</p><p>&nbsp;</p><p><em>Renal artery stenosis</em></p><p>Medication that affects the renin-angiotensin-aldosterone system, including angiotensin-II receptor antagonists (AIIRAs), may increase blood urea and serum creatinine levels in patients with bilateral renal or arterial stenosis of a single kidney.</p><p><em>&nbsp;</em></p><p><em>Intravascular volume depletion</em></p><p>Symptomatic hypotension may occur in patients with intravascular volume and/or sodium deficiency, as described for other substances affecting the renin-angiotensin-aldosterone system. Therefore, the use of Codiceran is not recommended unless this condition has been corrected.</p><p>&nbsp;</p><p><em>Anaesthetics and surgery</em></p><p>Hypotension may occur due to a blockade of the renin-angiotensin system in patients being treated with AIIRAs, under anaesthetic and during surgical intervention. On rare occasions, this hypotension may be serious enough to warrant the intravenous administration of fluids and/or vasopressor medication.</p><p><strong>&nbsp;</strong></p><p><em>Impaired liver function</em></p><p>Thiazides should be used with caution in patients with hepatic impairment or progressive liver disease, as even minor changes in fluid and electrolyte balance can trigger hepatic coma. There is no clinical experience with Codiceran in patients with hepatic impairment.</p><p><strong>&nbsp;</strong></p><p><em>Aortal and mitral valve stenosis (obstructive, hypertrophic cardiomyopathy)</em></p><p>As is the case with other vasodilators, special care is indicated in patients suffering from haemodynamically relevant aortal or mitral valve stenosis or obstructive hypertrophic cardiomyopathy.</p><p><strong>&nbsp;</strong></p><p><em>Primary hyperaldosteroneism</em></p><p>Patients with primary hyperaldosteroneism generally do not respond to medication to reduce blood pressure that acts by inhibiting the renin-angiotensin-aldosterone system. Thus, the administration of Codiceran is not recommended for this patient group.</p><p>&nbsp;</p><p><em>Electrolyte imbalance</em></p><p>Regular determination of serum electrolytes should be performed at appropriate intervals. Thiazides, including hydrochlorothiazide, may cause fluid or electrolyte imbalances (hypercalcaemia, hypokalaemia, hyponatraemia, hypomagnesaemia and hypochloraemic alkalosis).</p><p>&nbsp;</p><p>Thiazide diuretics may reduce renal calcium excretion and temporarily lead to slightly elevated serum calcium levels. Marked hypercalcemia may be a sign of hidden parathyroid hyperfunction. Thiazides should be discontinued before parathyroid function testing is performed.</p><p>&nbsp;</p><p>Hydrochlorothiazide increases renal potassium excretion in a dose-dependent manner, which can lead to hypokalemia. This effect of hydrochlorothiazide appears to be less pronounced in combination with candesartancilexetil. A greater risk of hypokalaemia exists in patients with hepatic cirrhosis, in patients undergoing forced diuresis, in patients with insufficient oral electrolyte intake and in patients on concomitant treatment with corticosteroids or adrenocorticotropic hormone (ACTH).</p><p>&nbsp;</p><p>Treatment with candesartan cilexetil may cause hyperkalemia, particularly in the presence of heart failure and/or impaired renal function. The concomitant use of Codiceran with ACE inhibitors, aliskiren, potassium-sparing diuretics, potassium preparations or potassium-containing salt substitutes or other medicinal products that can increase the serum potassium level (e.g., heparin sodium, co-trimoxazole also known as trimethoprim/sulfamethoxazole) can lead to increases in serum potassium levels. Potassium levels should be checked as required.</p><p>Thiazides have been shown to increase the renal excretion of magnesium, which can lead to hypomagnesemia.</p><p><strong>&nbsp;</strong></p><p><em>Metabolic and endocrine effects</em></p><p>Treatment with a thiazide diuretic may negatively affect glucose tolerance. Adjustment of the dose of antidiabetic medication, including insulin, may therefore be required. Latent diabetes mellitus may manifest during treatment with thiazide. Increases in cholesterol and triglyceride levels have been associated with thiazide diuretic therapy. Only minimal effects have been reported with the doses contained in Candesartan/HCT Sandoz. Thiazide diuretics increase serum uric acid concentration and may cause gout in predisposed patients.</p><p>&nbsp;</p><p><em>Photosensitivity</em></p><p>Cases of photosensitivity during the use of thiazide diuretics have been described (see Section&nbsp;4.8). If photosensitivity occurs, it is recommended to stop treatment. If resumption of treatment is required, it is recommended to protect those areas exposed to the sun or artificial UVA rays.</p><p>&nbsp;</p><p><em>Non-melanocytic skin cancer</em></p><p>In two epidemiological studies based on the Danish national cancer registry, an increased risk of non-melanocytic skin cancer (NMSC) [basal cell carcinoma (BCC) and squamous cell carcinoma (SCC)] was observed with increasing cumulative doses of hydrochlorothiazide (HCTZ). Photosensitising effects of HCTZ may contribute to the development of NMSC.</p><p>&nbsp;</p><p>Patients taking HCTZ should be informed about the risk of NMSC and should be advised to regularly check their skin for new lesions and report any suspicious skin changes immediately. Potential preventive measures to minimise the risk of skin cancer should be recommended to these patients, e.g., limiting exposure to sunlight and UV radiation, or, in the event of exposure, use of appropriate sun protection. Suspicious skin changes should be examined immediately, including histological examinations of biopsies if necessary. The use of HCTZ should be reviewed in patients who have already experienced NMSC (see also Section&nbsp;4.8).</p><p><em>&nbsp;</em></p><p><em>Choroidal effusion, acute myopia and secondary angle closure glaucoma</em></p><p>Sulphonamides and sulphonamide derivatives may trigger an idiosyncratic reaction, which may lead to choroidal effusion with visual field defects, transient myopia and acute angle closure glaucoma. The symptoms include the acute occurrence of reduced visual acuity or eye pain and typically occur within hours to weeks of the start of treatment. Untreated acute angle closure glaucoma can lead to permanent vision loss. The treatment of first choice is to stop the drug as soon as possible. Immediate surgical or medical procedures should be considered if intraocular pressure remains uncontrollable. A risk factor for the development of angle closure glaucoma could be a pre-existing sulfonamide or penicillin allergy.</p><p>&nbsp;</p><p><em>General information</em></p><p>Patients whose vascular tone and renal function overwhelmingly depend on the activity of the renin-angiotensin-aldosterone system (e.g., patients with serious congestive cardiac insufficiency or underlying renal disease, including renal arterial stenosis), acute hypotension, azotemia, oliguria and &ndash; in rare cases &ndash; acute renal failure have been associated with treatment with medication influencing this system, including AIIRAs. As is the case with any medication to reduce blood pressure, an excessive drop in blood pressure in patients suffering from ischaemic heart disease or arteriosclerotic cerebrovascular disease may result in myocardial infarction or a stroke.</p><p>Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with a corresponding history.</p><p>Aggravation or recurrence of systemic lupus erythematosus has been reported with thiazide diuretics.</p><p>&nbsp;</p><p>The antihypertensive effect of Codiceran can be intensified by other antihypertensives.</p><p>&nbsp;</p><p><em>Acute respiratory toxicity</em></p><p>Very rare severe cases of acute respiratory toxicity, including acute respiratory distress syndrome (ARDS), have been reported after taking hydrochlorothiazide. Pulmonary oedema typically develops within minutes to hours after taking hydrochlorothiazide. Symptoms include dyspnoea at onset, fever, worsening of lung function, and hypotension. If ARDS is suspected, Codiceran should be discontinued and appropriate treatment initiated. Hydrochlorothiazide should not be used in patients who have experienced ARDS after taking hydrochlorothiazide.</p><p>&nbsp;</p><p><em>Pregnancy</em></p><p>Treatment with AIIRAs should not be initiated during pregnancy. Patients planning pregnancy should be changed to alternative antihypertensive treatments which have an established safety profile for use in pregnancy unless the continuation of treatment with AIIRAs is absolutely necessary. When pregnancy is confirmed, treatment with AIIRAs should be discontinued immediately and, if required, alternative therapy should be initiated (see Sections 4.3 and 4.6).</p><p>&nbsp;</p><p><em>Doping controls </em></p><p>The use of Codiceran can lead to positive results in doping controls due to the ingredient hydrochlorothiazide.</p><p><em>&nbsp;</em></p><p><em>Warnings regarding excipients</em></p><p>This medicine contains lactose. Patients with rare hereditary galactose intolerance, complete lactase deficiency or glucose-galactose malabsorption should not take this medicine.</p><p>&nbsp;</p><p>This medicine contains less than 1&nbsp;mmol of sodium (23&nbsp;mg) per tablet, i.e., it is virtually &ldquo;sodium-free&rdquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The substances investigated in clinical pharmacokinetic studies include warfarin, digoxin, oral contraceptives (i.e., ethinylestradiol/levonorgestrel), glibenclamide and nifedipine. No clinically relevant pharmacokinetic interactions were determined in these studies.</p><p>&nbsp;</p><p>The potassium-lowering effect of hydrochlorothiazide could be expected to be amplified by other drugs that in turn may cause potassium loss and hypokalemia (e.g., other potassium diuretics, laxatives, amphotericin, carbenoxolone, penicillin G sodium, salicylic acid derivatives, steroids, ACTH).</p><p>&nbsp;</p><p>The concomitant use of Codiceran and potassium-sparing diuretics, potassium preparations or potassium-containing salt substitutes or other medicinal products that can increase the serum potassium level (e.g., heparin sodium, co-trimoxazole also known as trimethoprim/sulfamethoxazole), may lead to increases in the serum potassium levels. Where required, potassium levels should be monitored (see Section&nbsp;4.4).</p><p>&nbsp;</p><p>Diuretic-induced hypokalemia and hypomagnesemia predispose to the potentially cardiotoxic effects of digitalis glycosides and antiarrhythmics. Regular monitoring of serum potassium levels is recommended when Codiceran is used together with such medicinal products and with the following medicinal products that could cause torsades de pointes:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class Ia anti-arrhythmic agents (e.g., quinidine, hydroquinidine, disopyramide)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Class III anti-arrhythmic agents (e.g., amiodarone, sotalol, dofetilide, ibutilide)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Some antipsychotics (e.g., thioridazine, chloropromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Others (e.g., bepridil, cisapride, diphemanil, intravenous erythromycin, halofantrin, ketanserin, mizolastin, pentamidine, sparfloxacine, terfenadine, intravenous vincamine)</p><p>&nbsp;</p><p>Reversible increases in serum lithium concentrations and toxic effects were reported in patients using angiotensin-converting-enzyme (ACE) inhibitors or hydrochlorothiazide and lithium simultaneously. A similar effect has also been reported in AIIRAs. The use of candesartan and hydrochlorothiazide in combination with lithium is not recommended. Where this combination is essential, careful monitoring of serum lithium levels is recommended.</p><p>&nbsp;</p><p>Where AIIRAs are administered simultaneously with non-steroidal, anti-inflammatory medication (NSAIDs) (i.e., selective COX-2 inhibitors, acetylsalycylic acid (&gt;3&nbsp;g/day) and with non-selective NSAIDs), this may result in a weaker blood pressure-lowering effect.</p><p>&nbsp;</p><p>As is the case with ACE inhibitors, the simultaneous administration of AIIRAs and NSARs may result in an increased risk of deteriorating renal function, including potentially acute renal failure, as well as to an increase in serum potassium levels, especially in patients with pre-existing poor renal function. The combination should be administered with care, particularly in elderly patients. Patients should be sufficiently hydrated and monitoring of the renal function should be considered at regular intervals after starting concomitant treatment.</p><p>The diuretic, natriuretic and blood pressure lowering effects of hydrochlorothiazide are attenuated by NSAIDs.</p><p>&nbsp;</p><p>The resorption of hydrochlorothiazide is reduced by colestipol and cholestyramine.</p><p>&nbsp;</p><p>The effect of non-depolarising muscle relaxants (e.g., tubocurarine) can be increased by hydrochlorothiazide.</p><p>&nbsp;</p><p>Thiazide diuretics can increase the serum calcium level due to decreased excretion. If calcium supplements or vitamin D needs to be prescribed, calcium levels should be checked and the dosage adjusted accordingly.</p><p>&nbsp;</p><p>The hyperglycaemic effect of beta-blockers and diazoxide can be enhanced by thiazides.</p><p>&nbsp;</p><p>Anticholinergics (e.g., atropine, biperiden) may increase the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and gastric emptying speed.</p><p>&nbsp;</p><p>Thiazides may increase the risk of amantadine-mediated reactions.</p><p>&nbsp;</p><p>Thiazides may reduce the renal excretion of cytotoxic medicines (e.g., cyclophosphamide, methotrexate) and enhance their myelosuppressant effect.</p><p>&nbsp;</p><p>Orthostatic hypotension may be increased with concomitant use of alcohol, barbiturates, or anaesthetics.</p><p>&nbsp;</p><p>Treatment with a thiazide diuretic may negatively affect glucose tolerance. Adjustment of the dose of antidiabetic medication, including insulin, may therefore be required. Metformin should be taken with caution due to the risk of possible lactic acidosis induced by possible functional renal failure in combination with hydrochlorothiazide.</p><p>&nbsp;</p><p>Hydrochlorothiazide can lead to a reduced arterial reaction to blood pressure-increasing amines (e.g., adrenaline), but not to the extent that a blood pressure-increasing effect is excluded.</p><p>&nbsp;</p><p>Hydrochlorothiazide may increase the risk of acute renal failure, particularly with high doses of iodinated contrast media.</p><p>&nbsp;</p><p>Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia and gout-like complications.</p><p>&nbsp;</p><p>Concomitant treatment with baclofen, amifostine, tricyclic antidepressants or neuroleptics may increase the blood pressure lowering effect and cause hypotension.</p><p>&nbsp;</p><p>Data from clinical trials has shown that dual blockade of the renin-angiotensin-aldosterone system (RAAS) by concomitant use of ACE-inhibitors, angiotensin II receptor antagonists or aliskiren is associated with a higher rate of adverse events such as hypotension, hyperkalaemia, and impairment of renal function (including acute renal failure) as compared with the use of a single agent acting on the RAAS (see Sections&nbsp;4.3, 4.4, and 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em><u>Pregnancy</u></em></p><p>&nbsp;</p><p><em>Angiotensin-II receptor antagonists (AIIRAs):</em></p><p><em>&nbsp;</em></p><p>The administration of AIIRAs is not recommended during the first trimester of pregnancy (see Section 4.4). The administration of AIIRAs during the second and third trimesters of pregnancy is contraindicated (see Sections 4.3 and 4.4).</p><p>&nbsp;</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however, a slightly increased risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with Angiotensin II receptor inhibitors (AIIRAs), similar risks may exist for this class of drugs. Where the continuation of the AIIRA treatment is not regarded as essential, patients planning to become pregnant should be switched to alternative anti-hypertensive treatment with an appropriate safety profile for pregnant women. If pregnancy is confirmed, treatment with AIIRAs should be discontinued immediately and, if appropriate, alternative treatment should be initiated.</p><p>&nbsp;</p><p>Exposure to AIIRA therapy during the second and third trimesters of pregnancy is known to induce foetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia) (see also Section 5.3).</p><p>In the event of exposure to AIIRAs from the second trimester of the pregnancy onwards, ultrasound examinations of the renal function and the skull are recommended.</p><p>Infants whose mothers have taken AIIRAs should be repeatedly examined for hypotension (see also Sections 4.3 and 4.4).</p><p>&nbsp;</p><p><em>Hydrochlorothiazide:</em></p><p>There is limited experience in the use of hydrochlorothiazide during pregnancy, especially during the first trimester. The results of studies on animals are insufficient.</p><p>Hydrochlorothiazide crosses the placental barrier. Due to the pharmacological mechanism of action of hydrochlorothiazide, its use during the second and third trimesters of pregnancy may result in a disturbance of foeto-placental perfusion and in foetal and neonatal effects such as icterus, electrolyte imbalances and thrombocytopenia.</p><p>Due to the risk of decreased plasma volume and placental hypoperfusion and due to its lack of positive effect on the course of illness, hydrochlorothiazide should not be taken to treat pregnancy-related oedema, pregnancy-related hypertension or pre-eclampsia.</p><p>In the event of essential hypertension in pregnant women, hydrochlorothiazide should only be used in rare cases in which no other treatment is possible.</p><p>&nbsp;</p><p><em><u>Breastfeeding</u></em></p><p>&nbsp;</p><p><em>Angiotensin-II receptor antagonists (AIIRAs): </em></p><p>As no information is available regarding the use of Codiceran during breastfeeding, Codiceran is not recommended and alternative anti-hypertensive treatments with more suitable safety profiles are preferable during breastfeeding, especially while nursing a newborn or preterm infant.</p><p>&nbsp;</p><p><em>Hydrochlorothiazide:</em></p><p>Hydrochlorothiazide is released into human milk in small amounts. Thiazides, at high doses that cause intense diuresis, may inhibit milk production. The use of Codiceran during breastfeeding is not recommended.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No studies on the effects on the ability to drive and use machines have been conducted. When driving or operating machines, it should be taken into account that dizziness or fatigue may occasionally occur during treatment with Candesartan/HCT Sandoz.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In controlled clinical studies with candesartan cilexetil/hydrochlorothiazide, the side effects were slight and transient. Discontinuations due to adverse events were similar for candesartan cilexetil/hydrochlorothiazide (2.3-3.3%) and placebo (2.7-4.3%).</p><p>&nbsp;</p><p>In clinical studies with candesartan cilexetil/hydrochlorothiazide, side effects were limited to those previously reported with candesartan cilexetil and/or hydrochlorothiazide:</p><p>&nbsp;</p><p>The table below shows the side effects of candesartan cilexetil observed during clinical studies and based on experience following marketing of the product. A summarised analysis of the data obtained during clinical studies conducted on patients with hypertension defined the side effects of candesartan cilexetil on the basis of the frequency of side effects, which was at least 1% higher than the frequency reported with placebo.</p><p>&nbsp;</p><p>The frequencies given in the tables throughout Section 4.8 are as follows: very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), occasional (&ge;1/1,000 to &lt;1/100), rare (&ge;/10,000 to &lt;1/1,000) and very rare (&lt;1/10,000), not known (frequency cannot be estimated from the available data).</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" align="left" style="width:619px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and parasitic infestations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Respiratory tract infections</p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia and</p><p>Agranulocytosis</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Hyperkalaemia, hyponatremia</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness/vertigo, Headache</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Cough</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Nausea</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Diarrhoea</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Elevated liver enzyme values, liver dysfunction or hepatitis</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Angio-oedema, skin rash, urticaria, pruritus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Backache, arthralgia, Myalgia</p></td></tr><tr><td style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Restriction of renal function, including renal failure in susceptible patients (see Section 4.4)</p></td></tr></tbody></table><p>&nbsp;</p><p>The following table lists side effects with hydrochlorothiazide monotherapy at a dose of usually 25&nbsp;mg or higher.</p><p>&nbsp;</p><table border="1" cellspacing="0" cellpadding="0" style="width:624px"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td><td style="vertical-align:top"><p><strong>Adverse reaction</strong></p></td></tr><tr><td style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Leukopenia, neutropenia/agranulocytosis, thrombocytopenia, aplastic anaemia, bone marrow depression, haemolytic anaemia,</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td></tr><tr><td style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Hyperglycaemia, hyperuricemia, electrolyte imbalance (including hyponatremia and hypokalemia)</p></td></tr><tr><td style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Sleep disturbance, depressions, anxiety</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Dizziness, drowsiness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Paraesthesia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Temporarily blurred vision</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Choroidal effusion, acute myopia, acute angle closure glaucoma</p></td></tr><tr><td style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Cardiac arrhythmia</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Orthostatic hypotension</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Necrotizing angiitis (vasculitis, cutaneous vasculitis)</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Respiratory distress (including pneumonitis and pulmonary oedema)</p></td></tr><tr><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top"><p>Acute respiratory distress syndrome (ARDS) (see Section 4.4)</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Anorexia, loss of appetite, stomach irritation, diarrhoea, constipation</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Pancreatitis</p></td></tr><tr><td style="vertical-align:top"><p>Hepatobiliary disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Jaundice (intrahepatic cholestatic jaundice)</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rash, urticaria, photosensitivity</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td></tr><tr><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Systemic lupus erythematosus,</p><p>Cutaneous lupus erythematosus</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Muscle cramps</p></td></tr><tr><td style="vertical-align:top"><p>Benign, malignant and unspecified neoplasms (including cysts and polyps)</p></td><td style="vertical-align:top"><p>Not known</p></td><td style="vertical-align:top"><p>Non-melanocytic skin cancer (basal cell carcinoma and squamous cell carcinoma)*</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Glucosuria</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Renal dysfunction and interstitial nephritis</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Weakness</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Fever</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Increase in cholesterol and triglycerides</p></td></tr><tr><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Increase in BUN and serum creatinine</p></td></tr></tbody></table><p>&nbsp;</p><p>*Non-melanocytic skin cancer: Based on the available data from epidemiological studies, a cumulative dose-dependent relationship between HCTZ and NMSC was determined (see also Sections&nbsp;4.4 and 5.1).</p><p><u>&nbsp;</u></p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Saudi Arabia:</strong></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
 <v:stroke joinstyle="miter"/>
 <v:path gradientshapeok="t" o:connecttype="rect"/>
</v:shapetype><v:shape id="Text_x0020_Box_x0020_7" o:spid="_x0000_s1026"
 type="#_x0000_t202" style='position:absolute;margin-left:0;margin-top:-23.75pt;
 width:429pt;height:104.9pt;z-index:251659264;visibility:visible;
 mso-wrap-style:square;mso-width-percent:0;mso-height-percent:0;
 mso-wrap-distance-left:9pt;mso-wrap-distance-top:0;mso-wrap-distance-right:9pt;
 mso-wrap-distance-bottom:0;mso-position-horizontal:absolute;
 mso-position-horizontal-relative:margin;mso-position-vertical:absolute;
 mso-position-vertical-relative:text;mso-width-percent:0;mso-height-percent:0;
 mso-width-relative:margin;mso-height-relative:margin;v-text-anchor:top'
 o:gfxdata="UEsDBBQABgAIAAAAIQC75UiUBQEAAB4CAAATAAAAW0NvbnRlbnRfVHlwZXNdLnhtbKSRvU7DMBSF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" fillcolor="window" strokeweight=".5pt">
 <v:path arrowok="t"/>
 <v:textbox>
  <![if !mso]>
  <table cellpadding=0 cellspacing=0 width="100%">
   <tr>
    <td><![endif]>
    <div>
    <p class=MsoPlainText><span lang=DE style='font-family:"Arial",sans-serif'><span
    style='mso-spacerun:yes'> </span>NPC contact information Saudi Arabia:<o:p></o:p></span></p>
    <p class=MsoPlainText><span lang=DE style='font-family:"Arial",sans-serif'><o:p>&nbsp;</o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo1'><![if !supportLists]><span lang=DE
    style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=DE
    style='font-family:"Arial",sans-serif'>The National Pharmacovigilance
    Centre (NPC):<o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo1'><![if !supportLists]><span lang=DE
    style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=DE
    style='font-family:"Arial",sans-serif'>SFDA Call Center: 19999<o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo1'><![if !supportLists]><span lang=DE
    style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=DE
    style='font-family:"Arial",sans-serif'>E-mail: </span><span lang=DE><a
    href="mailto:npc.drug@sfda.gov.sa"><span style='font-family:"Arial",sans-serif'>npc.drug@sfda.gov.sa</span></a></span><span
    lang=DE style='font-family:"Arial",sans-serif'><o:p></o:p></span></p>
    <p class=MsoPlainText style='margin-left:.5in;text-indent:-.25in;
    mso-list:l0 level1 lfo1'><![if !supportLists]><span lang=DE
    style='font-family:"Courier New";mso-fareast-font-family:"Courier New"'><span
    style='mso-list:Ignore'>o<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;
    </span></span></span><![endif]><span dir=LTR></span><span lang=DE
    style='font-family:"Arial",sans-serif'>Website ade.sfda.gov.sa<o:p></o:p></span></p>
    <p class=MsoNormal><span lang=DE style='font-family:"Arial Unicode MS",serif;
    mso-fareast-font-family:"Arial Unicode MS";mso-bidi-font-family:"Arial Unicode MS"'><o:p>&nbsp;</o:p></span></p>
    </div>
    <![if !mso]></td>
   </tr>
  </table>
  <![endif]></v:textbox>
 <w:wrap anchorx="margin"/>
</v:shape><![endif]--><img width="578" height="146" alt="Text Box:  NPC contact information Saudi Arabia:

o	The National Pharmacovigilance Centre (NPC):
o	SFDA Call Center: 19999
o	E-mail: npc.drug@sfda.gov.sa
o	Website ade.sfda.gov.sa

" src="file:///C:/Users/aldakmo1/AppData/Local/Temp/1/msohtmlclip1/01/clip_image001.gif" /><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p>&nbsp;</p><p><strong>&bull;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other GCC states:</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</strong></p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Symptoms</em></p><p>Based on pharmacological considerations, it is probable that an overdose of candesartan cilexetil will manifest mainly as symptomatic hypotension and dizziness. Patients recovered without problems in individual overdose cases (of up to 672&nbsp;mg candesartan cilexetil).</p><p>&nbsp;</p><p>The main manifestation of an overdose of hydrochlorothiazide is acute fluid and electrolyte loss. Symptoms such as dizziness, hypotension, thirst, tachycardia, ventricular arrhythmias, sedation/clouding of consciousness, and muscle cramps may also be observed.</p><p>&nbsp;</p><p><em>Measures</em></p><p>There is no specific information on the treatment of an overdose with Candesartan/HCT Sandoz. However, the following measures are proposed in the event of overdose.</p><p>&nbsp;</p><p>If necessary, initiation of vomiting or gastric lavage should be considered. Symptomatic hypotension that may occur should be treated symptomatically and under vital signs monitoring. The patient should be placed on their back with legs raised. Where this is insufficient, the plasma volume should be increased by infusion of a physiological saline solution. Serum electrolyte and acid balance should be controlled and corrected if necessary. Where the above measures are insufficient, sympathomimetic medication may be given.</p><p>&nbsp;</p><p>Candesartan cannot be removed by haemodialysis. It is not known to what extent hydrochlorothiazide is eliminated by haemodialysis.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group angiotensin II antagonists + diuretics</p><p>ATC code: C09DA06</p><p><u>&nbsp;</u></p><p><u>Mechanism of action</u></p><p>Angiotensin&nbsp;II is the primary vaso-active hormone of the renin-angiotensin-aldosterone system and plays a role in the pathophysiology of high blood pressure and other cardiovascular diseases. It is also of significance in the pathogenesis of organ hypertrophy and end organ damage. The main physiological effects of angiotensin&nbsp;II, such as vasoconstriction, aldosterone stimulation, regulation of the salt and water homeostasis and stimulation of cell growth, are conveyed via the receptor subtype 1 (AT<sub>1</sub>).</p><p>&nbsp;</p><p><u>Pharmacodynamic effects</u></p><p>Candesartan cilexetil is a prodrug that is rapidly changed into the active form of candesartan by ester hydrolysis during resorption from the gastro-intestinal tract. Candesartan is an AIIRA selective for the AT<sub>1</sub>-receptor, which strongly binds to the receptor and gradually dissociates from it. It has no agonistic activity.</p><p>&nbsp;</p><p>Candesartan does not affect ACE or other enzyme systems normally associated with the use of ACE inhibitors. Because there are no effects on the breakdown of kinins or the metabolism of other substances, such as substance P, AIIRAs are unlikely to be associated with cough. In controlled clinical comparative studies carried out with candesartan cilexetil and ACE inhibitors, the frequency of coughing among patients receiving candesartan cilexetil was lower. Candesartan neither binds with nor blocks other hormone receptors or ion channels, which are known to be significant for cardiovascular regulation. The antagonism of the AT<sub>1</sub> receptor results in a dose-dependent increase in the plasma renin level, angiotensin&nbsp;I and angiotensin&nbsp;II levels and to a reduction in the plasma aldosterone concentration.</p><p>&nbsp;</p><p><u>Clinical efficacy and safety</u></p><p>The effect of candesartancilexetil 8-16&nbsp;mg (average dose 12&nbsp;mg) once daily on cardiovascular morbidity and mortality was observed in a randomised clinical study carried out on 4,937 elderly patients (70-89&nbsp;years; 21% aged 80&nbsp;years and older) with light to moderate hypertension over an average period of 3.7 years (Study on Cognition and Prognosis in the Elderly). The patients received candesartan or placebo in addition to other blood pressure-lowering treatment as required. In the candesartan group, blood pressure was reduced from 166/90 to 145/80&nbsp;mmHg, while in the control group this reduction was from 167/90 to 149/82&nbsp;mmHg. There was no statistically significant difference in the primary end point, serious cardiovascular events (cardiovascular mortality, non-fatal strokes and non-fatal myocardiac infarctions). In the candesartan group, there were 26.7 events per 1,000 patient years, compared with 30.0 events per 1,000 patient years in the control group (relative risk 0.89; 95% CI 0.75 to 1.06; p&nbsp;=&nbsp;0.19).</p><p>&nbsp;</p><p>Hydrochlorothiazide inhibits active reabsorption of sodium, mainly in the distal renal tubules, and promotes the excretion of sodium, chloride, and water. The renal excretion of potassium and magnesium increases in a dose-dependent manner, while calcium is reabsorbed to a greater extent. Hydrochlorothiazide decreases plasma volume and extracellular fluid and decreases cardiac output and blood pressure. In long-term therapy, decreased peripheral resistance contributes to blood pressure reduction.</p><p>&nbsp;</p><p>Large clinical studies have shown that long-term treatment with hydrochlorothiazide reduces the risk of cardiovascular mortality and morbidity.</p><p>&nbsp;</p><p>Candesartan and hydrochlorothiazide have additive antihypertensive effects.</p><p>&nbsp;</p><p>In patients with hypertension, candesartan/HCT causes a dose-dependent, long-lasting reduction in arterial blood pressure without reflective increase in heart rate. There are no indications of any serious or excessive first-dose hypotension or any rebound effect after discontinuation of treatment. Following the administration of a single dose of candesartan cilexetil/hydrochlorothiazide, the anti-hypertensive effect usually sets in within 2&nbsp;hours. With continuous therapy, the antihypertensive effect is essentially achieved within 4&nbsp;weeks and is maintained with long-term treatment. Candesartan/HCT once a day results in an effective and gentle reduction in blood pressure for a period of 24&nbsp;hours, with little difference between the maximum and minimum effects during the dosing interval. In a double-blind, randomised study, Codiceran 16&nbsp;mg/12.5&nbsp;mg once daily significantly reduced blood pressure and controlled significantly more patients than a combination of losartan/hydrochlorothiazide 50&nbsp;mg/12.5&nbsp;mg once daily.</p><p>&nbsp;</p><p>In double-blind, randomised studies, the incidence of adverse events, particularly dry cough, was lower with Codiceran than with a combination of ACE inhibitors and hydrochlorothiazide.</p><p>&nbsp;</p><p>In two clinical studies (randomised, double-blind, placebo-controlled, parallel groups) with 275 and 1,524 randomised patients, the Candesartan cilexetil/hydrochlorothiazide combinations 32&nbsp;mg/12.5&nbsp;mg and 32&nbsp;mg/25&nbsp;mg led to reductions in blood pressure of 22/15&nbsp;mmHg and 21/14&nbsp;mmHg respectively, and were significantly more effective than the respective monocomponents.</p><p>&nbsp;</p><p>In a randomised, double-blind, parallel-group clinical trial of 1,975 randomised patients who were not optimally controlled by candesartan cilexetil 32&nbsp;mg once daily, the addition of 12.5&nbsp;mg or 25&nbsp;mg hydrochlorothiazide brought about additional reductions in blood pressure. The candesartan cilexetil/hydrochlorothiazide combination of 32&nbsp;mg/25&nbsp;mg was significantly more effective than the 32&nbsp;mg/12.5&nbsp;mg combination and the total mean blood pressure reductions were 16/10&nbsp;mmHg and 13/9&nbsp;mmHg, respectively.</p><p>&nbsp;</p><p>Candesartan cilexetil/hydrochlorothiazide is just as effective in patients regardless of age and sex.</p><p>&nbsp;</p><p>There is currently no data on the use of candesartan cilexetil/hydrochlorothiazide in patients with renal disease/nephropathy, reduced left ventricular function/congestive heart failure and after myocardial infarction.</p><p><strong>&nbsp;</strong></p><p><em><u>Dual blockade of the renin-angiotensin-aldosterone system (RAAS)</u></em></p><p>In two large randomised, controlled studies (&ldquo;ONTARGET&rdquo; [ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial] and &ldquo;VA NEPHRON-D&rdquo; [Veterans Affairs Nephropathy in Diabetes]) the concomitant use of an ACE inhibitor with an angiotensin II receptor was investigated.</p><p>The &ldquo;ONTARGET&rdquo; study was conducted in patients with a history of cardiovascular or cerebrovascular disease or with type&nbsp;2 diabetes mellitus accompanied by evidence of end organ damage. The &ldquo;VA NEPHRON-D&rdquo; study was conducted on patients with type&nbsp;2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney failure and/or hypotension as compared to monotherapy was observed. Based on comparable pharmacodynamic properties, these results may also be transferred to other ACE inhibitors and angiotensin&nbsp;II receptor antagonists. This is why ACE inhibitors and angiotensin&nbsp;II receptor antagonists should not be used concomitantly in patients suffering from diabetic nephropathy.</p><p>The &ldquo;ALTITUDE&rdquo; study (Aliskiren Trial in Type&nbsp;2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or angiotension II receptor antagonist in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated prematurely on account of an increased risk of adverse reactions. Cases of both cardiovascular death and strokes occurred numerically more frequently in the aliskiren group than in the placebo group, and similarly, this was also true of adverse reactions and particularly serious adverse reactions (hyperkalaemia, hypotension and renal dysfunction).</p><p>&nbsp;</p><p>Non-melanocytic skin cancer: Based on the available data from epidemiological studies, a cumulative dose-dependent relationship between HCTZ and NMSC was observed. One study included a basic population of 71,533 cases of BCC and 8,629 cases of SCC with control groups of 1,430,833 or 172,462 people. A high hydrochlorothiazide dose (&ge;50,000&nbsp;mg cumulative) was associated with an adjusted odds ratio of 1.29 (95% confidence interval: 1.23-1.35) for BCC and 3.98 (95% confidence interval: 3.68-4.31) for SCC. A clear cumulative dose-effect relationship was determined for both BCC and SCC. Another study showed a possible connection between lip cancer (SCC) and exposure to HCTZ: 633 cases of lip cancer were compared with a control group of 63,067 persons using a risk-oriented sampling procedure. A cumulative dose was found to have a relationship between the effects with an adjusted odds ratio of 2.1 (95% confidence interval: 1.7-2.6), which at high exposure (~&nbsp;25,000&nbsp;mg) was reduced to an odds ratio of 3.9 (3.0‑4.9) and at the highest cumulative dose (~&nbsp;100,000&nbsp;mg), also increased to an odds ratio of 7.7 (5.7-10.5) (see also Section 4.4).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The concomitant administration of candesartan cilexetil and hydrochlorothiazide has no clinically significant effects on the pharmacokinetics of the other medicinal product.</p><p>&nbsp;</p><p><em><u>Absorption and distribution</u></em></p><p><em>&nbsp;</em></p><p><em>Candesartancilexetil</em></p><p>Following oral administration, candesartancilexetil is converted into the active form candesartan. The absolute bio-availability of candesartan is about 40% when an oral candesartancilexetil solution has been taken. The relative bio-availability of the tablet formulation of candesartancilexetil compared to the same formulation as an oral solution amounts to approximately 34%, with very low variability. Mean maximum serum concentration (C<sub>max</sub>) is reached 3-4&nbsp;hours after tablet intake. There is a linear increase in the candesartan serum concentration with increasing doses within the treatment dosage range. Gender-specific differences in the pharmacokinetics of candesartan were not observed. The area below the serum concentration/time curve (AUC) for candesartan is not significantly influenced by food intake.</p><p>&nbsp;</p><p>Candesartan is bound to plasma protein to a high degree (over 99%). The apparent distribution volume of candesartan is 0.1&nbsp;l/kg.</p><p><em>&nbsp;</em></p><p><em>Hydrochlorothiazide</em></p><p>Hydrochlorothiazide is rapidly resorbed from the gastrointestinal tract with an absolute bioavailability of approximately 70%. Concurrent food intake increases absorption by approximately 15%. Bioavailability may decrease in patients with heart failure and marked oedema.</p><p>&nbsp;</p><p>The plasma protein binding of hydrochlorothiazide is approx. 60%. The apparent distribution volume is approx. 0.8&nbsp;l/kg.</p><p><em><u>&nbsp;</u></em></p><p><em><u>Biotransformation and excretion</u></em></p><p><em>&nbsp;</em></p><p><em>Candesartancilexetil</em></p><p>Candesartan is mainly excreted unchanged in the urine and bile and only metabolised in the liver to a negligible extent (CYP2C9). Existing interaction studies did not show any effects on CYP2C9 and CYP3A4. Based on <em>in vitro</em> data, no <em>in vivo </em>interactions are expected with substances, the metabolism of which depends on the cytochrome P450 isoenzymes CYP1A2, CYP2A6, CYP2C9, CYP2C19, CYP2D6, CYP2E1 or CYP3A4. The terminal half-life (t<sub>&frac12;</sub>) of candesartan is approximately 9&nbsp;hours. There is no cumulative effect following the administration of several doses. The half-life of candesartan remains unchanged (approximately 9&nbsp;hours) after administration of candesartan cilexetil in combination with hydrochlorothiazide. After repeated administration of the combination, there is no additional accumulation of candesartan compared to monotherapy.</p><p>&nbsp;</p><p>The total plasma clearance of candesartan is approximately 0.37&nbsp;ml/min/kg, with a renal clearance of about 0.19&nbsp;ml/min/kg. Renal excretion of candesartan takes place by means of glomerular filtration and by active tubular secretion. Following an oral dose of <sup>14</sup>C-radioactive marked candesartan cilexetil, approximately 26% of the dose is excreted in the urine in the form of candesartan and 7% as an inactive metabolite, while approximately 56% of the dose was found in the faeces in the form of candesartan and 10% as an inactive metabolite.</p><p><em>&nbsp;</em></p><p><em>Hydrochlorothiazide</em></p><p>Hydrochlorothiazide is not metabolised and is almost completely excreted as unchanged active substance by glomerular filtration and active tubular secretion. The terminal t<sub>1/2</sub> of hydrochlorothiazide is approximately 8&nbsp;hours. Approx. 70% of an oral dose is eliminated in urine within 48&nbsp;hours. The half-life of hydrochlorothiazide remains unchanged (approximately 8&nbsp;hours) after administration of hydrochlorothiazide in combination with candesartan cilexetil. After repeated administration of the combination, there is no additional accumulation of hydrochlorothiazide compared to monotherapy.</p><p>&nbsp;</p><p><em><u>Pharmacokinetics in special populations</u></em></p><p><em>&nbsp;</em></p><p><em>Candesartancilexetil</em></p><p>In older people (aged over 65&nbsp;years), the C<sub>max</sub> and AUC of candesartan are increased by approximately 50% or 80% in comparison with young test subjects. The response of the blood pressure and the frequency of side effects are similar after administration of a dose of candesartancilexetil to young and old patients, however (see Section 4.2).</p><p>&nbsp;</p><p>In patients with slightly to moderately reduced renal function, the C<sub>max</sub> and AUC values for candesartan increased by approximately 50% and 70% with repeated doses in comparison with patients with normal renal function; but the terminal t<sub>1/2 </sub>remained unchanged. The corresponding changes in patients with a serious reduction in renal function amounted to approximately 50% and 110% respectively. The terminal t<sub>1/2 </sub>of candesartan approximately doubled in patients with seriously reduced renal function. The pharmacokinetics in dialysis patients was similar to that of patients with a serious reduction in renal function.</p><p>&nbsp;</p><p>In two studies, both of which involved patients with slightly to moderately reduced liver function, there was an increase in the average AUC of candesartan of approximately 20% in one study and 80% in the other study (see Section 4.2). No data is available on patients with severe hepatic impairment.</p><p><em>&nbsp;</em></p><p><em>Hydrochlorothiazide</em></p><p>Hydrochlorothiazide terminal t<sub>1/2</sub> is prolonged in patients with impaired renal function.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Compared to the individual components, there were no qualitatively new toxicological findings for the combination. In preclinical safety studies, candesartan had an effect on the kidneys and the red blood cell parameters (erythrocytes, haemoglobin, haematocrit) when administered in high doses to mice, rats, dogs and monkeys. Effects on the kidneys (such as regeneration, dilation and basophilia of the tubuli; increased plasma concentrations of urea and creatinine) were caused by candesartan, which might be as a consequence of its hypotensive effect resulting in changes in kidney perfusion. The addition of hydrochlorothiazide increases the nephrotoxicity of candesartan. In addition, candesartan resulted in hyperplasia/hypertrophy of the juxtaglomerular cells. It is assumed that these changes are caused by the pharmacological activity of candesartan and are of little clinical relevance.</p><p>&nbsp;</p><p>Foetotoxicity of candesartan has been observed in late pregnancy. The addition of hydrochlorothiazide did not significantly affect the outcome of foetal development studies in rats, mice and rabbits (see Section 4.6).</p><p>&nbsp;</p><p>Candesartan and hydrochlorothiazide both show genotoxic activity in very high concentrations/doses. Data from <em>in vitro</em> and <em>in vivo </em>genotoxicity tests show that candesartan and hydrochlorothiazide are unlikely to have mutagenic or clastogenic effects when used clinically.</p><p>&nbsp;</p><p>There was no evidence that either substance is carcinogenic.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Codiceran 16&nbsp;mg/12.5&nbsp;mg &ndash; tablets</em></p><p>Lactose monohydrate</p><p>Corn starch</p><p>Povidone K-30</p><p>Carrageenan (E 407)</p><p>Croscarmellose sodium</p><p>Magnesium stearate</p><p>Iron oxide, red (E172)</p><p>Iron oxide yellow (E172)</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>Store in the original package</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Al/Al Blister with desiccant: 28 tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Sandoz GmbH
Biochemiestrasse 10, 6250 Kundl, Austria

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                June 2022
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>